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WILL THE FDA's 2010 WARFARIN LABEL CHANGES FINALLY
PROVIDE THE LEGAL IMPETUS FOR WARFARIN
PHARMACOGENETIC TESTING?
Susan A. Fuchs*
Due to newer clinical utility study results and the recent
availability of warfarin pharmacogenetic testing, the Food and
Drug Administration ("FDA") has modified warfarin's
prescription labeling twice in the past three years. Yet, despite
numerous warfarin dosing adverse events resulting from trial and
error dosing, many clinicians have been reluctant to prescribe
warfarin pharmacogenetic testing to increase dosing accuracy.
This disparity stems from conflicts over the interpretations and
results of warfarin pharmacogenetic clinical utility studies. Until
the federal government implements independent clinical
effectiveness testing authorized by the 2010 Patient Protection and
Affordable Care Act, manufacturers, health care institutions, and
health care clinicians have the unenviable task of sorting through
this morass. This article examines the clinical utility of warfarin
pharmacogenetic tests, the FDA's role, and other contributing
factors that have an impact on the liability and practice of those
responsible for the tests' implementation.
I. INTRODUCTION
In a 2006 national pharmaceutical survey, 74% of consumers
admitted that they had not followed their prescribers' directions for
taking their prescription medications, including 31% who had not
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O'Connor College of Law; 1980 J.D., Cleveland-Marshall College of Law; 1976
B.A. magna cum laude, University of Cincinnati. Ms. Fuchs would like to thank
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gotten a prescription filled.' This prescription noncompliance may
be related to the fact that 25% to 50% of medications are
ineffective in a given patient, necessitating costly and inefficient
trial and error prescribing.2
In contrast to this scatter-shot, trial and error approach, the goal
of personalized medicine is to more accurately predict an
individual's response to therapy based on unique individual
characteristics, such as the patient's genetic makeup. Accurate,
clinically useful, pharmacogenetic tests4 allow a health care
clinician to individually target patient medication and dosages.
Such targeted therapy may improve patient medication adherence
because the medication and dosage are more likely to be effective
and less likely to have adverse effects.
' Press Release, Nat'l Cmmty. Pharms. Assoc., Take as Directed A
Prescription Not Followed (Dec. 15, 2006) (on file with the Journal of Law &
Technology).
2 Matthew Avery, Personalized Medicine and Rescuing "Unsafe" Drugs with
Pharmacogenomics: A Regulatory Perspective, 65 FOOD & DRUG L. J. 37, 40
(2010).
Medco, Predictions: Five Insights that Will Shape Healthcare, 10 DRUG
TREND REPORT 1, 89 (2008), available at
http://medco.mediaroom.com/file.php/1 62/2008+DRUG+TREND+REPORT.pd
f.
4 Pharmacogenetic tests test for genetic mutations (polymorphisms). U.S.
DEP'T OF HEALTH AND HUMAN SERVS.: FOOD & DRUG ADMIN., GUIDANCE FOR
INDUSTRY AND FDA STAFF: PHARMACOGENETIC TESTS AND GENETIC TESTS
FOR HERITABLE MARKERS 3 (June 19, 2007) [hereinafter FDA, GUIDANCE FOR
PHARMACOGENETIC TESTS], available at
http://www.fda.gov/downloads/MedicalDevices/
DeviceRegulationandGuidance/GuidanceDocuments/ucm071075.pdf. The
purpose of pharmacogenetic tests in clinical settings is to delineate whether a
particular therapy (medication in the case of warfarin) or dosage is appropriate
for a patient given the patient's genetic mutations and pharmacogenetic
polymorphisms in conjunction with the patient's other clinical information. Id.
In contrast, a clinician seeks a genetic test in order to determine a patient's risk
of acquiring a disease or condition. Id. Pharmacogenetics is the same as
pharmacogenomics; the author uses both terms interchangeably in this paper.
5 Medco, supra note 3, at 90.
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Due to increasing evidentiary support for warfarin'
pharmacogenetic testing, the Food and Drug Administration
("FDA") has modified warfarin prescription labeling twice in the
past three years.' Yet, despite numerous warfarin dosing adverse
events resulting from the trial and error approach, many clinicians
have been reluctant to prescribe warfarin pharmacogenetic testing
to increase dosing accuracy.! Few question the analytical validity
of FDA approved warfarin pharmacogenetic tests, but there is
considerable disagreement over whether the tests offer any real
clinical usefulness or utility for the medical practitioner.
Numerous concerns have hampered widespread adoption of
pharmacogenetic testing by clinicians: high costs, health insurance
coverage issues, slow test result turnaround times, time constraints
for clinician office visits, lack of informed consent, availability of
genetic resources, and insufficient patient and clinician education.
Independent clinical effectiveness testing, authorized by the 2010
Patient Protection and Affordable Care Act ("PPACA"),' might
help to clarify the above concerns, but the Act's measures will not
be implemented for several years.o Meanwhile, pharmaceutical
manufacturers, pharmacists, health care institutions, and health
care clinicians have the unenviable task of sorting through warfarin
pharmacogenetic testing concerns without the benefit of PPACA's
independent clinical effectiveness testing. This article focuses on
warfarin pharmacogenetic testing as an example of both the
promises and the limitations of genetic personalized medicine. It
6 Unless specified otherwise in this paper, warfarin refers to warfarin sodium,
the generic name for the brand named drug, Coumadin, manufactured by
Bristol-Myers Squib Company. BRISTOL-MYERS SQUIBB CO., COUMADIN
TABLETS (WARFARIN SODIUM TABLETS, USP) CRYSTALLINE, COUMADIN FOR
INJECTION (WARFARIN SODIUM FOR INJECTION, USP) at I (Supp. No. 108, 2010)
[hereinafter BRISTOL-MYERS SQUIBB Co. (2010)] available at
http://www.accessdata.fda.gov/drugsatfda docs/label/2010/009218s1081bl.pdf.
7 BRISTOL-MYERS SQUIBB Co., COUMADIN TABLETS (WARFARIN SODIUM
TABLETS, USP) CRYSTALLINE, COUMADIN FOR INJECTION (WARFARIN SODIUM
FOR INJECTION, USP) 25 (Supp. No. 105, 2007) [hereinafter BRISTOL-MYERS
SQUIBB Co. (2007)].
8 See infra Parts II.A.3.
9 Patient Protection and Affordable Care Act of 2010, Pub. L. 11-148, 124 Stat.
119 (2010).
'
0Pub. L 111-148 §1004.
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examines the clinical utility of warfarin pharmacogenetic tests and
the consequences that the FDA's and health insurers' actions have
on the liability and practice of those responsible for
implementation of the tests.
II. WARFARIN AND PHARMACOGENETIC TESTING
Warfarin is a prescription medication within the class of
anticoagulant drugs." Without sufficient anticoagulation in a
patient susceptible to blood clots, the patient risks death or tissue
damage, depending upon where in the body the blood clot blocks
or ruptures a blood vessel.12 A drug in this class can prevent a
stroke from a coagulation that restricts blood flow in the brain, 3
limits lung damage that would have resulted from a clot induced
pulmonary embolism, 4 and discourages other blood starved tissue
injuries from clots that migrate and block blood vessels elsewhere
in the body." Anticoagulants are often prescribed when blood
pools in a patient's heart, a byproduct of ineffective heartbeats
from atrial fibrillation. Avoidance of clotting in the pooled blood
" BRISTOL-MYERS SQUIBB Co. (2010), supra note 6 at 1. Anticoagulants
inhibit the blood's ability to coagulate or clot. Anticoagulant Drugs, AM.
HEART Ass'N, http://www.americanheart.org/presenter.jhtml?identifier-155
(last visited Nov. 10, 2010); Arixtra, Fragmin, Innohep, and Lovenox Injection,
FOOD & DRUG ADMIN. (Jan. 10, 2010),
http://www.fda.gov/Safety/MedWatch/Safetylnformation/ ucml96983.htm
[hereinafter FDA, Arixtra]. They do not dissolve existing blood clots or reverse
any tissue damage caused by those clots. Id; BRISTOL-MYERS SQUIBB Co.
(2010), supra note 6, at 3. They are used preventively to limit clots from
developing, lessen the growth of existing clots, and minimize resulting tissue
damage. Other anticoagulant prescription drugs include fondaparinux,
dalteparin, danaparoid, enoxaparin, heparin, and tinzaparin. Anticoagulant
Drugs, AM. HEART Ass'N, http://www.americanheart.org/
presenter.jhtml?identifier-155 (last visited Nov. 10, 2010).
12 BRISTOL-MYERS SQUIBB Co. (2010), supra note 6, at 3.
13 A stroke's clot induced blood loss destroys surrounding brain tissue.
Gregory W. Albers, et al., Antithrombotic and Thrombotic Therapy for Ischemic
Stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic
Therapy, 126 CHEST J. 483S, 484S (2004).
14 Anticoagulant Drugs, AM. HEART ASS'N, http://www.americanheart.org/
presenter.jhtml?identifier-155 (last visited Nov. 10, 2010).
" BRISTOL-MYERS SQUIBB Co. (2010), supra note 6, at 3.
102 [VOL. 12: 99
Pharmacogenetic Testing for Warfarin
helps to protect the patient from a myocardial infarction or stroke.'"
Anticoagulants are also indicated to prevent the clotting process
("thrombosis") in patients with a history of thrombosis, or in
patients who are more likely to have increased clotting due to
cardiac valve and joint replacements."
A. Advantages and Disadvantages ofAvailable Anticoagulants
1. Warfarin
a. Warfarin's Moldy Origins
Scientist Karl Paul Link and his colleagues fractionated a
concentrate of the active hemorrhagic ingredient in spoiled hay
that was responsible for killing cattle." After testing the
concentrate on laboratory rabbits, they discovered that it increased
the rabbits' blood clotting time ("prothrombin time"), resulting in
hemorrhages.20 Link realized that vitamin K-deficient animals
16 Heart & Vascular Center: Atrial Fibrillation, BARNES JEWISH HOSP.,
http://www.barnesjewish.org/heart-vascular/atrial-fibrillation-treatment (last
visited Nov. 30, 2010). A myocardial infarction ("heart attack") causes heart
muscle damage from the clots blocking blood flow. Heart Attack, MERRIAM-
WEBSTER'S MED. DICTIONARY, http://www2.merriam-webster.com/cgi-
bin/mwmedsamp (last visited Nov. 30, 2010).
1 Kirsten Neudoerffer Kangelaris et al., Genetic Testing Before
Anticoagulation? A Systematic Review ofPharmacogenetic Dosing of Warfarin,
24 J. GEN. INTERNAL MED. 656, 658 (2009).
'
8Antithrombotic drugs consist of anticoagulant, thrombolytic and antiplatelet
drug classes. Pharma Companies in R&D Battle as Warfarin Goes on,
Datamonitor Researchstore (Oct. 25, 2005), http://www.datamonitor.com/
store/News/pharma companies in rd battle as warfaringoes on?productid=9
B9CC5Al-5984-4DD5-A227-EB5552E37A21. This scope of this paper is not
broad enough to include a discussion of all antithrombotic medications.
'9 The impetus for Karl Paul Link's warfarin research began in 1933 when a
frustrated Wisconsin farmer drove his truck loaded with a heifer that had bled to
death; a milk can full of uncoagulated cattle blood; and a mound of moldy,
spoiled, sweet clover hay to Link's laboratory at the University of Wisconsin.
Societal Contributions, Wis. ALUMNI RES. FOUND.,
http://www.warf.org/about/index.jsp?cid=26&scid=34 (last visited Nov 30,
2010); Nicole Kresge, et al., Hemorrhagic Sweet Clover Disease, Dicumarol,
and Warfarin: the Work of Karl Paul Link, 280 J. BIOLOGICAL CHEMISTRY e5,
e6 (2005).
20 Harold A. Campbell et al., Studies on the Hemorrhagic Sweet Clover
Disease: 1. The Preparation of Hemorrhagic Concentrates, 136 J. BIOLOGICAL
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and dicumarol-fed laboratory rabbits had similar hemorrhages,
noting that vitamin K has a similar structure to dicumarol. This led
to Link's use of vitamin K to reverse dicumarol's anticoagulation
properties.2 1
b. Warfarin's Mechanism ofAction as an Anticoagulant
Warfarin is the only vitamin K antagonist available in the
United States.22 Vitamin K is a cofactor that activates several of
CHEMISTRY 47, 50-54 (1940). This is a modification of a naturally occurring
plant chemical, coumarin. ROBERT H. BURRIS, KARL PAUL LINK: 1901-1978
186-187 (1994). They named the compound that they isolated "dicumarol."
Kresge et al., supra note 19, at e6. The compound, C, 9HI206 , has the formula
3,3'-methylenebis (4-hydroxycoumarin). Mark Arnold Stahmann et al., Studies
on the Hemorrhagic Sweet Clover Disease: V Identification and Synthesis of
the Hemorrhagic Agent, 138 J. BIOLOGICAL CHEMISTRY 513, 513 (1941). See
Charles Ferdinand Huebner & Karl Paul Link, Studies on the Hemorrhagic
Sweet Clover Disease: VI. The Synthesis of the 3-Diketone Derived from the
Hemorrhagic Agent through Alkaline Degradation, 138 J. BIOLOGICAL
CHEMISTRY 529, 531 (1941) (discussing the scientists' synthetically derived
dicumarol).
2 Kresge et al., supra note 19, at e6. In 1941, after a brief period of clinical
testing, dicumarol began to be used as a human anticoagulant. Id. Link and his
colleagues synthesized more than 100 dicumarol analogues including the
rodenticide, warfarin. Id. One of Link's students and coauthors, Mark
Stahmann, saw the potential of this analogue that Link had abandoned because
of its toxicity; Stahmann patented warfarin as a rodenticide. Id. Warfarin is
named after the Wisconsin Alumni Research foundation or WARF that funded
the patent process. DAVID NELSON & ROBERT BURRIS, MEMORIAL RESOLUTION
OF THE FACULTY OF THE UNIVERSITY OF WISCONSIN-MADISON: ON THE DEATH
OF PROFESSOR EMERITUS MARK ARNOLD STAHMANN 1 (Faculty Document
1617, Mar. 2002). Link's colleagues later developed a more soluble warfarin
derivative for human use, warfarin sodium, which replaced the less potent
dicumarol. Id. at 18.; Jerold A. Last, Profiles in Toxicology-The Missing Link:
The Story ofKarl Paul Link, 66 TOxICOLOGICAL SCI. 4, 4 (2002). The warfarin
patented as a rodenticide is a different warfarin compound from warfarin
sodium, the generic of Coumadin. Last supra at 4. DuPont Pharmaceuticals
was the first manufacturer to own the rights to warfarin sodium. History,
BRISTOL-MYERS SQUIBB Co.,
http://www.bms.com/ourcompany/Pages/history.aspx (last visited Apr. 2, 2010).
They sold it under the brand name Coumadin until 2001, when Bristol-Meyers
Squibb purchased DuPont Pharmaceuticals, along with the rights to Coumadin.
Id.
22 A vitamin K antagonist is a chemical that counteracts or neutralizes the
affects of vitamin K. Antagonist, MERRIAM WEBSTER'S MED. DICTIONARY,
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the proteins that cause blood to coagulate ("clotting factors").23
The body has limited stores of vitamin K, so the body cyclically
regenerates existing vitamin K for reuse.24 During this
regeneration process, the enzyme vitamin K epoxide reductase
("VKOR") converts the inactive form of vitamin K ("vitamin K
epoxide") into the active form of vitamin K. Warfarin inhibits
the VKOR enzyme's ability to change vitamin K epoxide back into
vitamin K. This results in less vitamin K available to facilitate the
activation of clotting factors such as Factor II ("prothrombin").2 6
Ultimately, this creates an increase in prothrombin time: less
prothrombin activation slows the conversion of prothrombin into
thrombin,2 7 making less thrombin available to alter fibrinogen into
fibrin to form blood clots.
2. Heparin and Low Molecular Weight Heparin Mechanisms of
Action
http://www2.merriam-webster.com/cgi-bin/mwmedsamp (last visited Nov. 30,
2010). Warfarin is a synthetic dicumarol which is a hydroxycoumarin
derivative. Coumarin is a natural plant chemical. Although warfarin is the only
synthetically created dicumarol/coumarin derivative in the U.S., two other
derivatives, phenprocoumon and acenocoumarol, are sold in some European
countries. All three dicumarol/coumarin derivatives are vitamin K antagonists.
Vitamin K Antagonist, Warfarin, Warfarin Therapy, THROMBOSIS ADVISER,
http://www.thrombosisadviser.com/scripts/pages/en/ thrombosis/warfarin.php
(last visited Apr. 3, 2010).
23 Hugh M. Robertson, Genes Encoding Vitamin-K Epoxide Reductase Are
Present in Drosophila and Trypanosomatid Protists, 168 GENETICS 1077, 1077
(2004).
24 Jane Hidgon, Micronutrient Information Center: Vitamin K, OR. ST. U.
LINUS PAULING INST., http://lpi.oregonstate.edu/infocenter/vitamins/vitaminK/
(last updated May 2008).
25 Robertson, supra note 23, at 1077; Jack Ansell et al., Pharmacology and
Management of the Vitamin K Antagonists: American College of Chest
Physicians Evidence-Based Clinical Practice Guidelines (8'h Edition), 133
CHEST J. 160S (2008).
26 Higdon, supra note 24. Coumarin based anticoagulants also depress
Factors VII, IX, and X as well as Proteins C and S. BRISTOL-MYERS SQUIBB
Co. (2010), supra note 6, at 2-3. In the 1940s, Karl Paul Link first realized that
this increase in prothrombin time is the same in subjects who had taken
warfarin's precursor as in subjects who had vitamin K deficiencies. See supra
notes 20-21 and accompanying text.
27 Last, supra note 21, at 4.
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Heparin ("heparin" or "unfractionated heparin") and low-
molecular-weight heparin ("LMW heparin" or "fractionated
heparin") enhance the effect of antithrombin to inhibit factors Xa
and Ha ("thrombin").2 8 When antithrombin inactivates these
factors, it prevents fibrinogen from clotting.29 Both heparin and
LMW heparins are associated with increased risks of heparin-
induced thrombocytopenia ("HIT") syndrome, which can be fatal,
and osteoporosis.30
3. Diferences between Warfarin and Heparin/LMWHeparin
Although the anticoagulation result is the same using warfarin
as it is with fractionated or unfractionated heparin, warfarin and
heparins make thrombin unavailable to fibrinogen through
different pathways. Since heparins are not vitamin K antagonists,
clinicians can prescribe warfarin and heparin concurrently.' A
clinician may start a patient on one of the heparins because their
anticoagulant affects are quite rapid, often occurring within 24
hours.32 It can take four to five days to get a warfarin international
normalized ratio ("INR") response within the therapeutic range."
28 Umesh R. Desai, Heparins, VCU SCHOOL OF PHARMACY,
http://www.people.vcu.edu/~urdesai/hep.htm (last revised Jan. 5, 2000). Factors
Xa and Ila are the two main procoagulant proteases. Id.
29 Id.
30 There is some controversy over whether there is less of a risk of HIT with
LMW heparin than with heparin. Theodore E. Warkentin & Andreas
Greinacher, So, Does Low-Molecular- Weight Heparin Cause Less Heparin-
Induced Thrombocytopenia Than Unfractionated Heparin or Not?, 132 CHEST J.
1108, 1109 (2007).
3' BRISTOL-MYERS SQUIBB Co. (2010), supra note 6, at 29. ; David A. Garcia
et al., Delivery of Optimized Anticoagulant Therapy: Consensus Statement from
the Anticoagulation Forum, 42 THE ANNALS OF PHARMACOTHERAPY 979, 985
(2008).
32 In one study, patients achieved activated partial thromboplastin time
("APTT") ratios and heparin therapeutic blood levels in 24 hours, 71% of the
time, when they received continuous intravenous heparin, versus 37% of the
time when they received heparin subcutaneously. Jack Hirsh et al., Heparin and
Low-Molecular- Weight Heparin Mechanisms of Action, Pharmacokinetics,
Dosing, Monitoring, Efficacy, and Safety, 119 CHEST J. 64S, 67S (2001).
3 The INR is a standardized method of rating an oral anticoagulant (such as
warfarin) patient's prothrombin time ("PT") blood test results into a ratio using
an international sensitivity index reference. This PT ratio is used internationally
106 [VOL. 12: 99
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The advantage of warfarin over heparins is that warfarin is
available orally as a pill,34 while the others are only available as
injectables." The warfarin pill allows a patient to easily self-
administer the medication as an outpatient. 6 LMW heparin is not
as convenient as warfarin, but usually more so than unfractionated
heparin. A patient can self-administer most LMW heparins
subcutaneously instead of requiring a hospital stay for intravenous
heparin.17
The issue of hospitalization is important for managing the cost
of anticoagulation therapy. Though heparin and some LMW
heparins are off-patent, hospital stays for intravenous
anticoagulation therapy are costly. In data collected from
to monitor oral anticoagulant patient dosing. International Normalized Ratio,
THE FREE DICTIONARY, http://medical-dictionary.thefreedictionary.com/
International+Normalized+Ratio (last visited June 19, 2010). Generally the
patient remains on heparin/LWM heparin for several days after a patient
achieves a warfarin INR greater than 2.0. Ansell et al., supra note 25.
34 BRISTOL-MYERS SQUIBB Co. (2010), supra note 6, at 1.
35 For information on anticoagulants ondaparinux, dalteparin, tinzaparin, and
enoxaparin, see FDA, Arixtra, supra note 11. For information on anticoagulant
danaparoid, see Center for Drug Evaluation and Research, Meeting ofAnesthetic
and Life Support Drugs, FOOD & DRUG. ADMIN., 15 (Feb. 5, 1998),
http://www.fda.gov/ohrms/dockets/ac/98/transept/3380tl.pdf. For information
on anticoagulant heparin, see Drugnfo: Heparin, MIMS USA,
http://www.mims.com/Page.aspx?menuid=mng&name=heparin&h=heparin,sodi
um&CTRY=US&searchstring=heparin+sodiumolution (last visited Apr. 2,
2010).
36 However, other oral anticoagulants may soon be available. Rivaroxaban, a
pill that reportedly inhibits the Xa clotting factor, is in phase III testing. Steven
Reinberg, New Anticoagulant Pill Works Well in Trial, HEALTHDAY NEWS
(June 17, 2009). Apizaban is another proposed Xa inhibitor undergoing phase II
and III trials. The thrombin inhibitor dabigatron looks promising in phase III
trials; although AstraZeneca withdrew another thrombin inhibitor, ximelagatran,
because of liver toxicity. Dave Levitan, New Drugs and Targets Promise
Change in Oral Anticoagulation, HEMONC TODAY (Mar. 25, 2008), available at
http://www.hemonctoday.com/article.aspx?rld=27221. A potential factor 1Xa
inhibitor, TTP889, is in phase II trials. Id..
3 For information on anticoagulant heparin, see DrugInfo: Heparin, MIMS
USA,
http://www.mims.com/Page.aspx?menuid=mng&name=heparin&h=heparin,sodi
um&CTRY=US&searchstring=heparin+sodiumolution (last visited Apr. 2,
2010).
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December 2006 through June 2008, an average hospital stay to
obtain a therapeutic INR range or to treat a bleeding episode is 4.8
days. 3 The median 4.8 day hospital cost is $10,419; patient costs
are higher.3 9 In contrast, warfarin is available generically and is
1,000 times less costly, at $10.83 for 100 7.5 milligram tablets of
warfarin.40 Warfarin's ease of self-administration and cost savings
have contributed to clinicians writing more than 30 million
warfarin prescriptions in 2004 alone.4'
B. Genetic Factors Affecting Warfarin Dosing
All anticoagulants have bleeding risks if a patient receives too
much, and clotting risks if a patient receives too little.4 2 Warfarin
has a narrow therapeutic range (a target INR of 2.5 with a range of
2.0-3 .0).43 A number of risk factors, including age, weight, sex,
drug and food interactions, and genetic factors, affect achieving
38 Andrea L. Long et al., Characteristics of Ambulatory Anticoagulant
Adverse Drug Events: A Descriptive Study, 8 THROMBOSIS J. 1, 3 (2010),
available athttp://www.thrombosisjournal.com/content/pdf/1477-9560-8-5.pdf.
39 id.
40 Pricing & Ordering Comparisons, All Prices for: Warfarin-Generic
Version, PHARMACYCHECKER, http://www.pharmacychecker.com/Pricing.asp?
DrugName=Warfarin&Drugld=19462&DrugStrengthld=33097 (last visited
Apr. 4, 2010). Even though warfarin is cheaper and easier to administer,
researchers in one study estimate that warfarin had the second highest level of
emergency department adverse drug events ("ADEs") in 2004 to 2005. Daniel
S. Budnitz et al., National Surveillance of Emergency Department Visits for
Outpatient Adverse Drug Events, 296 J. AM. MED. ASS'N 1858, 1864 (2006).
Heparin and LMW Heparins were not on the study's list of medications that
have 1% or more emergency department ADEs. Id.
41 The International Warfarin Pharmacogenetics Consortium, Estimation of
the Warfarin Dose with Clinical and Pharmacogenetic Data, 360 NEW ENG. J.
MED. 753, 753 (2009). Warfarin is the highest selling anticoagulant and one of
the top two selling antithrombotics. Heart & Vascular Center: Atrial
Fibrillation, BARNES JEWISH HosP., http://www.bamesjewish.org/heart-
vascular/atrial-fibrillation-treatment (last visited Nov. 30, 2010). Sanofi-
Aventis' antiplatelet drug, Plavix (generic drug is "clopidogrel"), is the other
highest selling antithrombotic. Id.
42 E.g., BRISTOL-MYERS SQUlBB Co. (2010), supra note 6.
43 BRISTOL-MYERS SQUIBB Co. (2010), supra note 6, at 20, 24.
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that narrow therapeutic range." Several known genetic factors that
affect warfarin dosage are in the CYP2C9 and VKORC1 genes.45
1. CYP2C9 DNA Sequence Variants
The Cytochrome P450 enzyme, in subfamily IIC, polypeptide
9, is also known as CYP2C9.46 It is the body's main metabolizing
enzyme for warfarin.4 7 Two frequent polymorphisms in the genes
that encode the enzyme, CYP2C9*24 8 and CYP2C9*3, are found
primarily in Caucasians.49 These polymorphisms are known to
affect how a person's body metabolizes warfarin."o
"Id. at 5-6, 26-27.
45 Id. at 5. The FDA has classified the CYP2C9*2, CYP2C9*3, and
VKORCl-1639G>A alleles as valid biomarkers. Table of Valid Genomic
Biomarkers in the Context of Approved Drug Labels, FOOD & DRUG ADMIN.
(Feb. 17, 2010), http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/
Pharmacogenetics/ucm083378.htm.
46 Hsiang-Yu Yuan et al., A Novel Functional VKORC1 Promoter
Polymorphism Is Associated with Inter-Individual and Inter-Ethnic Diferences
in Warfarin Sensitivity, 14 HUM. MOLECULAR GENETICS, 1745, 1745 (2005).
47 Id.
48 A human polymorphism is a genetic mutation that occurs in 1% or more of
people. What is a gene mutation and how do mutations occur?, GENETICS
HOME REFERENCE (Nov. 22, 2010), http://ghr.nlm.nih.gov/handbook/
mutationsanddisorders/genemutation. Polymorphisms are responsible for
normal human variations. Id. Some of these polymorphism variations are easily
perceived, such as blue eye color. Id. Others are invisible to the naked eye,
requiring genetic test results to reveal their genetic variations, such as the
CYP2C9*2 and CYP2C9*3 gene alleles. Id. In the CYP2C9*2 allele
polymorphism, 8-13% of the time, the cysteine amino acid substitutes for the
arginine amino acid. Robert D. McBane et al., Warfarin Sensitivity Genotyping:
Why? When? How to Use It to Best Advantage (Mar. 2010),
http://www.mayomedicallaboratories.com/tests/warfarin/warfarinvideo.html;
Yuan et al., supra note 46 at 1749. This polymorphism occurs much more
frequently in some racial groups than others. See infra notes 60-64, and
accompanying text. For Caucasians, the FDA estimates that CYP2C9*2 occurs
in 11%, while CYP2C9*3 occurs in 7%. BRISTOL-MYERS SQUIBB CO. (2010),
supra note 6, at 4 .
49 In the CYP2C9*3 polymorphism, 6-10% of the time, the leucine amino
acid substitutes for the isoleucine amino acid. McBane et al., supra note 48;
Yuan et al., supra note 46, at 1749.
50 Yuan et al., supra note 46, at 1747-48. People with African ancestry have
infrequent CYP2C9 enzyme activity in *5, *6, and *11 regions; Caucasians
have infrequent CYP2C9 enzyme activity in *5, *9, and * 11 regions. BRISTOL-
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CYP2C9*1 is the unmodified allele that does not contain a
polymorphism." The enzyme encoded by this allele metabolizes
warfarin more rapidly than the enzymes from CYP2C9*2 and
CYP2C9*3 alleles, so a patient having the *1 allele will need a
higher dose of warfarin than those with the *2 and *3
polymorphisms.5 The *3 polymorphism slows warfarin
metabolism more severely than a *2 polymorphism.53 Thus, this
slowed metabolic effect is compounded in a warfarin patient with
homozygous *3 alleles.
CYP2C9 polymorphisms do not have a direct impact on the
vitamin K cycle.54 Because the presence of CYP2C9*2 and
CYP2C9*3 alleles slow the metabolism of warfarin, more warfarin
is absorbed through smaller doses than from the presence of the
CYP2C9*1 allele. A patient with CYP2C9*1/*1 generally
requires the highest warfarin dose, while a patient with
CYP2C9*3/*3 generally requires the lowest dose, with the other
combinations in between. If both the CYP2C9*1/*1 patient and
the CYP2C9*3/*3 receive the same initial average dose, the latter
slow metabolizer has a greater hemorrhage risk.
2. VKORCl Gene
The VKORC1 gene" encodes the proteins responsible for the
vitamin K regeneration cycle." The identified polymorphism in
the VKORC 1 gene is not in the coding regions of the gene like it is
with CYP2C9 polymorphisms." Instead, the VKORCl gene has
MYERS SQUIBB Co. (2010), supra note 6, at 4 . People with Chinese ancestry
appear to rarely have CYP2C9*2 and CYP2C9*3 polymorphisms at all. Yuan
et al., supra note 46, at 1746.
s' McBane et al., supra note 44.
52 Id.; BRISTOL-MYERS SQUIBB Co. (2010), supra note 6, at 4.
5 Each *2 allele polymorphism is responsible for a 17% decrease in warfarin
metabolism when compared to a patient with CYP2C9*1/*1 alleles, whereas the
decrease is 37% per CYP2C9*3 allele. BRISTOL-MYERS SQUIBB CO. (2010),
supra note 6, at 5; McBane et al., supra note 48.
54 McBane et al., supra note 48.
ss The VKORCI gene encodes one subunit in the VKOR enzyme complex
("VKORC"). Robertson, supra note 23, at 1077.
56 McBane et al., supra note 48. See supra notes 22-27 and accompanying
text.
5 McBane et al., supra note 48.
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single nucleotide polymorphisms ("SNPs") in the promoter area of
the gene, particularly in the -1639 promoter site."
A patient who has a VKORC1-1639 G>A adenine nucleotide
("A") allele requires less warfarin than average to achieve the
target INR coagulation level; whereas, a patient who has a
VKORC1-1639 G guanine nucleotide ("G") allele requires a
higher dose of warfarin than average to achieve the target INR
coagulation level.5 9 Patients who receive average initial warfarin
dosing that have VKORC1-1639 GG alleles are likely to have
problems associated with blood clot formation (venous
thromboembolisms, strokes, heart attacks), while patients at the
other end of the spectrum with VKORCl-1639 AA alleles are at
risk for excessive bleeding. Either extreme can be deadly.
3. CYP2C9 and VKORCl Polymorphism Combinations
The CYP2C9 and VKORCI polymorphisms need to be
evaluated together because even though some alleles indicate that a
patient most likely requires a lower warfarin dose (CYP2C9*2,
CYP2C9*3, and VKORC1-1639 A), the VKORC1-1639 G and
CYP2C9*1 alleles indicate the opposite.60 As shown in the chart
below, a patient can have homozygous CYP2C9 and VKORC1
alleles from either extreme, heterozygous alleles, or a combination
of both."
Although some CYP2C9 and VKORC1 alleles may occur more
frequently in patients who have the same racial ancestry, CYP2C9
58BRISTOL-MYERS SQUIBB Co. (2010), supra note 6, at 5; Yuan et al., supra
note 46, at 1746. The VKORCl gene makes messenger ribonucleic acid
("mRNA") in the promoter area which regulates how the protein becomes
synthesized, ultimately leading to encoding of the VKORC1 proteins.
VKORC1-1639 represents 1,639 base pairs before the VKORCl starting codon.
McBane et al., supra note 48.
5 Yuan et al., supra note 46, at 1746. Thus, a patient with a VKORC-1639
GG base pair requires significantly more warfarin, while one with a VKORCl-
1639 AA base pair requires significantly less warfarin, and a heterozygous
patient with a VKORC1-1639 AG base pair is in-between. McBane et al., supra
note 48.
60 Yuan et al, supra note 46.
61 Per allele: *1 =high dose, less sensitive; G=high dose, less sensitive; *2 and
*3=low dose, more sensitive; and A=low dose, more sensitive.
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and VKORC1 warfarin pharmacogenetic testing is more accurate
than racial self-identification for predicting these warfarin genetic
sensitivities.62 Thus, clinicians do not need to risk incorrectly
evaluating a patient's racial ancestry as a factor separate from the
patient's CYP2C9 and VKORC1 genetic factors. For example, in
the Medco-Mayo Clinic Warfarin Effectiveness Study ("Medco-
Mayo study")," researchers used the same pharmacogenetic
dosage recommendations as in the 2010 Coumadin label. Even
though the study findings charted below indicated a prevalence of
some allele combinations in patients based on a patient's racial
ancestry, it omitted contradictory 2010 label suggestions about
separate dosage adjustments for self-identified racial ancestry.'
62 BRISTOL-MYERS SQUIBB CO. (2010), supra note 6, at 27.
63 See infra notes 111-20 and accompanying text.
6 See infra notes 183-85 and accompanying text.
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Table 1: Medco-Mayo Study Warfarin Dosing
Warfarin CYP2C9 VKO C = Cauca- Inci- + or - Coum
sensitivity RC1 sian dence to Base adin
AF = Dosage 2010
African dosage
AS =
Asian65
Low *1/*1 GG AF mostly 25.4% Dose + 5-7
sensitivity 20=/o6 mg
mg
Normal *1/*1 GA C mostly 29.2% Dose=5 5-7
sensitivity mg m
Mild *1/*2 GG 12.2% Dose - 5-7
sensitivity *1/*3 10%=5. mg
*2/*2 5 mg
Moderate *1/*2 GA 26.6% Dose - 3-4
sensitivity *1/*3 30%=3. mg
*2/*2 5 mg
*2/*3 GG
*1/*1 AA Almost all
AS here
High *2/*3 GA 4% Dose - 0.5-2
sensitivity 60% =2 mg
Very high *3/*3 G/A 2.6% Dose - 0.5-2
sensitivity *1/*3 AA >60%= mg
*2/*2 <2 mg +
*2/*3 frequent
*3/*3 INR
C base dose=5 mg 66
65 The main studies that this author found showing this genetic metabolism
effect are based on studies conducted in China with ethnic Chinese subjects. See
supra note 50 and infra note 93 and accompanying text. These same results
should not be generalized to all of Asia because the population in the other 46
ethnically diverse Asian countries does not necessarily have the same genetic
warfarin metabolism as do ethnic Chinese. See Jaekyu Shin et al.,
Pharmacogenetics: From Discovery to Patient Care, 66 AM. J. HEALTH-SYs.
PHARMACISTS 625, 629-30 (2009) for a discussion of two genetic haplotypes
that encompass this genetic metabolism effect.
66 McBane et al., supra note 48; Robert S. Epstein et al., Warfarin Genotyping
Reduces Hospitalization Rates: Results from the MM-WES (Medco-Mayo
Warfarin Effectiveness Study), 55 J. OF THE AM. COLL. OF CARDIOLOGY, 1, 3
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In 2008, Washington University's Brian Gage and fellow
researchers published a study in which they created an online
algorithm for dosing warfarin." As part of the study, they
evaluated the warfarin pharmacogenetic genotypes, body surface
area, target INR, smoking status, amiodarone use," race, and
thrombosis status in 1,015 warfarin study patients to develop the
pharmacogenetic algorithm. They also evaluated an additional 292
similar patients to validate their findings.69 Consistent with prior
studies, the results showed that clinical factors accounted for 17-
21% of dosage variations. By adding VKORC1-1639 G>A and
CYP2C9 genotypes, the factors accounted for 53-54% of dosing
variations.7 o The algorithm factors in clinical and/or genetic
information to calculate initial and revised doses based on
available patient information. Since first publishing the online
warfarin algorithm calculator, the researchers have replaced it with
at least 20 versions to update the site with new data gathered from
the site's participants.7 The result is a free, user-friendly, internet
(2010). The advantage of the Medco-Mayo Study Dosing Chart is that it gives
more specific dosing recommendations for specific allele combinations than
those in the Coumadin 2010 label. For instance, the Coumadin 2010 label gives
the same 5 to 7 milligram recommendation for all of the allele combinations
within the Medco-Mayo Study's categories of low, normal, and moderate
sensitivities. Although the Medco-Mayo Study's three sensitivity categories
contain recommendations within the same 5 to 7 milligram range, the study's
recommendations are 6, 5, and 5.5 milligrams for specific allele combinations in
each respective sensitivity category. BRISTOL-MYERS SQUIBB CO. (2010) supra
note 6.
67 WARFARIN DOSING, http://www.warfarindosing.org/Source/ Home.aspx
(last visited Apr. 3, 2010).
68 Amiodarone is a medication used to treat ventricular arrhythmias. Heart &
Vascular Center: Atrial Fibrillation, BARNES JEWISH HosP.,
http://www.barnesjewish.org/heart-vascular/atrial-fibrillation-treatment (last
visited Nov. 30, 2010)..
69 B. F. Gage et al., Use of Pharmacogenetic and Clinical Factors to Predict
the Therapeutic Dose of Warfarin, NIH PUBLIC ACCESS 1-2 (2008),
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683977/pdf/nihms-109988.pdf.
70 1d. at 3-4.
" WARFARIN DOSING, http://www.warfarindosing.org/Source/ Home.aspx
(last visited Apr. 3, 2010); Brian F. Gage, Version History, WARFARIN DOSING,
http://www.warfarindosing.org/Source/ShowToolTip.aspx (last visited May 7,
2010).
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calculator that takes into consideration more variables than in both
the Medco-Mayo study and the Coumadin 2010 label.72
C. Validity of Warfarin Pharmacogenetic Tests
In order for clinicians to be able to make effective treatment
decisions based on a patient's pharmacogenetic data, several
factors must be present. Tests need to be available that accurately
measure those data. In addition, the pharmacogenetic test
information must provide a clinical benefit that outweighs the
tests' risks. Furthermore, the clinician must be able to understand
the test results and the benefits. Finally, the patient or the insurer
must be willing to pay the associated costs.
1. Analytical Validity
A genetic test has analytical validity if it accurately and
reliably measures the genetic information that the test is designed
to measure." When a pharmacogenetic test manufacturer submits
a Food Drug and Cosmetic Act § 501(k) application to the FDA for
a pharmacogenetic test, the manufacturer must provide data to
prove the pharmacogenetic test's analytical validity.74  In
September of 2007, the FDA approved the first § 501(k) premarket
notification for a CYP2C9/VKORC1 genetic test system for
warfarin by Nanosphere, Inc., deeming the test to have sufficient
analytical validity. Three more warfarin pharmacogenetic test
72 The calculator takes into account the patient's status as a new patient:
beginning warfarin dose, age, sex, ethnicity (includes "unknown"), race
(includes "other"), weight, height, smoking, liver disease, reason for warfarin,
baseline INR, target INR, randomize and blind INR, amiodarone dose,
statin/HMG CoA reductase inhibitor, any azole drug (e.g., Fluconazole), any
sulfa drugs, VKORCl variables, CYP2C9 *2-*6 variables, CYP4F2 V433M
variables (CC, CT, TT), and GGCX rsl1676382 variables (CC, CG, GG).
WARFARIN DOSING, http://www.warfarindosing.org/Source/ Home.aspx (last
visited Apr. 3, 2010).
7 Shin et al., supra note 65, at 631.
74 FDA, GUIDANCE FOR PHARMACOGENETIC TESTS, supra note 4 at 6.
7 Nanosphere, Inc., Verigene Warfarin Metabolism Nucleic Acid Test and the
Verigene System 510(k) Summary, FOOD & DRUG ADMIN. (Sept. 17, 2007),
http://www.accessdata.fda.gov/cdrh docs/pdf7K070804.pdf [hereinafter FDA,
Nanosphere 510(k)].
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systems were approved by the FDA in 2008, and another was
approved in 2009."
2. Clinical Validity and Clinical Utility
A pharmacogenetic test should also have both clinical validity
and clinical utility. A test is clinically valid if it can predict a
patient's response to a drug therapy." Traditionally, a test has
clinical utility when a randomized controlled trial ("RCT")
assesses the balance of the risks and benefits of pharmacogenetic
testing including the risks and benefits of maintaining the status
quo, exploring other alternative treatments, and evaluating cost and
time efficiencies. 9 However, FDA directors Woodcock and Lesko
argue that comprehensive RCTs may not be necessary when
evaluating the clinical utility of warfarin pharmacogenetic testing.80
76 AutoGenomics, Inc., INFINITI 2C9 & VKORCI Multiplex Assay for
Warfarin 510(k) Summary, FOOD & DRUG ADMIN. (Jan. 23, 2008),
http://www.accessdata.fda.gov/cdrh docs/pdf7/K073014.pdf [hereinafter FDA,
AutoGenomics 510(k)]; Paragon DX, Rapid Genotyping Assay-CYP2C9 &
VKORClI 510(k) Summary, FOOD & DRUG ADMIN. (Apr. 28, 2008),
http://www.accessdata.fda.gov/cdrhdocs/pdf7/K071867.pdf [hereinafter FDA,
Paragon 510(k)]; Osmetech Molecular Diagnostics eSensor Warfarin Sensitivity
Test and eSensor XT-8 System 510(k) Summary, FOOD & DRUG ADMIN. (Jul.
17, 2008), http://www.accessdata.fda.gov/cdrh docs/pdf7/KO73720.pdf
[hereinafter FDA, Osmetech 510(k)].
n TrimGen Corp., eQ-PCR Warfarin Genotyping Kit 510(k) Summary, FOOD
& DRUG ADMIN. (Feb. 6, 2009), http://www.accessdata.fda.gov/cdrh docs/
pdf7/KO73071.pdf [hereinafter FDA, TrimGen 510(k)]. TrimGen Corporation,
AutoGenomics, Inc., and Osmetech Molecular Diagnostics demonstrated to the
FDA that their pharmacogenetic test systems will accurately identify
CYP2C9*2, CYP2C9*3, VKORCI-1639 A, and VKORCl-1639 G alleles. Id.;
FDA, AutoGenomics 5 10(k), supra note 76; FDA, Osmetech 5 10(k), supra note
76. Nanosphere, Inc. and Paragon Dx demonstrated to the FDA that their
pharmacogenetic test systems will accurately identify the same CYP2C9 alleles
as the three manufacturers above, as well as VKORCl 1173 T and VKORCl
1173 C alleles. FDA, Nanosphere 510(k), supra note 75; FDA, Paragon 510(k),
supra note 76.
78 Shin et al., supra note 65, at 631.
7 Id.
soianet Woodcock & Lawrence J. Lesko, Pharmacogenetics-Tailoring
Treatment for the Outliers, 360 NEW ENG. J. MED. 811, 813 (2009). Janet
Woodcock is Director of the FDA's Center for Drug Evaluation and Research
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They point out that pharmacogenetics has the potential to benefit
those statistical outliers at both ends of the spectrum who do not
have average responses." Given the small numbers of these
warfarin genetic outliers, it is not surprising that there is a lack of
information on genetic outliers in the larger warfarin patient
population and a scarcity of RCT studies.82 Woodcock and Lesko
conclude that these circumstances suggest that "less rigorous
approaches" than RCTs may be sufficient, such as studies that
focus on the warfarin genetic outliers instead of those in the
general warfarin population.83 Brian Gage concurs:
For new drugs, experts agree that randomized, controlled
trials are required to demonstrate safety and effectiveness.
In contrast, diagnostic tests can be validated against a gold
standard, thereby bypassing the need for [RCTs].84
One author in the pro-RCT camp criticized the clinical validity
of earlier warfarin pharmacogenetic studies because they had too
few subjects and none of the studies differentiated serious bleeding
complications." In 2008, the American College of Medical
Genetics Policy Statement concluded that there was insufficient
evidence to support routine testing of CYP2C9/VKORC 1 genes for
warfarin dosing.86 However, they felt it would be reasonable to use
CYP2C9/VKORCl pharmacogenetic testing to diagnose the
causes of unusually low warfarin maintenance doses or unusually
high INRs." Recently, researchers have completed several large
("CDER"), and Lawrence J. Lesko is Director of FDA's Office of Clinical
Pharmacology ( "OCP").
8 Id. at 112-113.
82 Id
83 Id.
84 Shannon Rose, Issue Stories: Pharmacogenetic Testing for Warfarin
Advances, CLINICAL LAB PROD. (July 2009),
http://www.clpmag.com/issues/articles/2009-07_01.asp.
85 Charles S. Eby, Point/Counterpoint, Pharmacogenetic-Based Initial Dosing
of Warfarin: Not Ready for Prime Time, 55 CLINICAL CHEMISTRY 712, 712-13
(2009).
86 David A. Flockhart et al., ACMG Policy Statement: Pharmacogenetic
Testing of CYP2C9 and VKORCl Alleles for Warfarin, 10 J. OF GENETIC MED.
139, 149 (2008).
" Id. at 150.
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studies and reviews that address some of these clinical validity and
clinical utility issues.
a. Centers for Medicare and Medicaid Services Decision
On August 3, 2009, the Centers for Medicare and Medicaid
Services ("CMS") published a thorough analysis of the clinical
utility of pharmacogenetic testing for warfarin." In the analysis,
CMS looked for whether a patient's warfarin pharmacogenetic test
results would cause a treating clinician to prescribe a different dose
of warfarin than the clinician would have prescribed without that
information and whether the different dose would improve patient
health outcomes.89 As discussed below, the CMS analysis
evaluated the 2007 Coumadin label, the positions of numerous
medical, cardiac, pulmonary, and genetic organizations, public
opinions, and available studies."
CMS reviewed the 2008 Tufts-New England Medical Center
Evidence-based Practice Center Review ("Tufts Review"), which
88 Memorandum from Ctrs. for Medicare & Medicaid Servs. on
Pharmacogenomic Testing for Warfarin Response (CAG-00400N) (Aug. 3,
2009), available at http://www.cms.hhs.gov/mcd/
viewdecisionmemo.asp?id=224 [hereinafter CMS]. CMS' statutory authority is
limited under 42 U.S.C. § 1395y(a)(1) (2006) of the Social Security Act to
reimbursement of expenses reasonably necessary for diagnosis, treatment, or
improvement in the "functioning of a malformed body member." CMS, supra
at 15.
89 CMS, supra note 88, at 16-17. Although Medicare does not cover
preventative diagnostic screening tests for an asymptomatic patient, it does
cover tests that will help the clinician to diagnose and treat a patient with an
existing condition. Id at 12. However, Medicare will begin to cover Medicare
preventive services on or after January 1, 2011. See Patient Protection and
Affordable Care Act , 42 U.S.C. §§ 1395y-1395z (2010).
90 CMS, supra note 88, at 4-14. The American Association for Clinical
Chemistry and the College of American Pathologists believe there is sufficient
clinical utility and validity evidence to warrant warfarin pharmacogenetic
testing. Id. at 13. The Association for Molecular Pathology, the American
Society of Hematology, the American College of Chest Physicians, and the
American College of Medical Genetics hold the opposite opinion. Id at 13-14.
CMS noted that although the American Medical Association promoted using
pharmacogenetic web sites, a physician would still need to monitor PT/lNR, and
testing has no pharmacogenetic value if the physician ignores food and more
than 300 drug interactions that require warfarin dosage adjustments. Id. at 14-
15.
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examined published studies from 1995 to 2007." CMS claimed
few of the Tufts Review studies addressed the patient health
benefits or harms that could be attributed to warfarin dosing guided
by pharmacogenetic testing ("clinical effectiveness").92 CMS also
dismissed the other studies it evaluated for similar reasons.93
9 Id. at 7-9.
"Id. at 9.
93 CMS, supra note 88, at 9-11. The 2005 meta-analysis by Sanderson
concluded that the evidence of clinical effectiveness was insufficient. Id. at 9;
Simon Sanderson et al., CYP2C9 Gene Variants, Drug Dose, and Bleeding Risk
in Warfarin-Treated Patients: A HuGEnetm Systematic Review and Meta-
Analysis, 7 GENETICS IN MED. 97, 97-104 (2005). In 2007, Millican conducted a
retrospective study finding that relying solely on INR for dosing increases the
chance of too little or too much warfarin dosing. Eric A. Millican et al.,
Genetic-Based Dosing in Orthopedic Patients Beginning Warfarin Therapy, 110
BLOOD 1511, 1513 (2007). CMS discounted the study because all of the study
participants received warfarin for the same indication. CMS, supra note 88, at
11. The 2008 McClain study found low associations between CYP2C9
pharmacogenetic testing and serious bleeding incidents, and no associations
between VKORCl and serious bleeds. Monica R. McClain et al., A Rapid-
ACCE Review of CYP2C9 and VKORCl Alleles Testing to Inform Warfarin
Dosing in Adults at Elevated Risk for Thrombotic Events to Avoid Serious
Bleeding, 10 GENETICS IN MED. 89, 97 (2008). A study by Schwarz in 2008
found that VKORC1 results predicted PT/INR warfarin response better than
CYP2C9 but did not address health benefits. Ute 1. Schwarz et al., Genetic
Determinants of Response to Warfarin During Initial Anticoagulation, 358 NEW
ENG. J. OF MED. 999, 1005-06 (2008). Wen's group studied the value of
pharmacogenetic testing in male Han Chinese without a comparison group. M-S
Wen et al., Prospective Study of Warfarin Dosage Requirements Based on
CYP2C9 and VKORC1 Genotypes, 84 Clinical Pharmacology & Therapeutics
83, 86-87 (2008). Wen's researchers noted that CYP2C9 genotyping was less
helpful since most Chinese have *1 alleles; the VKORC 1 genotyping allowed
the Chinese patients to reach stable INR levels sooner than in Caucasian studies
because of the narrower range of Chinese variability. Id.
The 2009 studies that CMS reviewed did not fare any better. The Wadelius
Scandinavian study concludes that VKORCl and CYP2C9 pharmacogenetic
testing predicts warfarin dosing sensitivity. Mia Wadelius et al., The Largest
Prospective Warfarin-Treated Cohort Supports Genetic Forecasting, 113
BLOOD 784, 790-91 (2009). CMS discounted the study because it was limited
to one ethnic group, and it did not consider weight and height in setting warfarin
dosages. CMS, supra note 88, at 11. Kangelaris' meta-analysis of three studies
from 2005-2007 concluded that few randomized studies found that initial dosing
based on pharmacogenetic test results reduced the number of major bleeds.
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CMS found limitations with the most recent study in its review,
the 2009 International Warfarin Pharmacogenetics Consortium
("Warfarin Consortium") study.9 4 The Warfarin Consortium
compared the clinical utility of warfarin pharmacogenetic-based
dosing with clinical and fixed dosing algorithms. 95 They enrolled
5,052 warfarin patients from nine countries, each with a target INR
between 2 to 3.96 The Warfarin Consortium developed three
dosage prediction models from a random selection of 80% (4,043)
of those patients: one from the patients' genetic information, one
from their clinical information, and one using a fixed dose.97 The
investigators tested the models on the remaining 20% (1,009) of
the patients.98
All three Warfarin Consortium study algorithms accurately
predicted dosing for 54% of the patients in the middle of the
dosing spectrum.9 9 The pharmacogenetic algorithm was only
statistically significant for 46% of patients who were farthest from
the dosing norm.' The pharmacogenetic algorithm predicted
accurate dosing for 54% of those patients who required 3 mg or
less warfarin per day. Whereas the clinical algorithm had a 33%
accuracy rate and the fixed dose model had 0% accuracy.o' The
Kangelaris et al., supra note 17, at 662. Li's study found that pharmacogenetic
testing allowed earlier predictions of INR results as its only predictive benefit.
Chun Li et al., Relative Contribution of CYP2C9 and VKORC1 Genotypes and
Early INR Response to the Prediction of Warfarin Sensitivity During Initiation
of Therapy, 113 BLOOD 3925, 3929-30 (2009). Lindh reviewed 39 studies in a
1999-2007 meta-analysis, noting that VKORCl data was too limited, as was
homozygous CYP2C9*2 and *3 because of the latter genotypes' rarity.
Jonathan D. Lindh et al., Influence of CYP2C9 Genotype on Warfarin Dose
Requirements-A Systematic Review and Meta-Analysis, 65 EUROPEAN J. OF
CLINICAL PHARMACOLOGY 365, 372 (2009).
94 CMS, supra note 88.
9 The International Warfarin Pharmacogenetics Consortium, supra note 35, at
753-62.
96 Id. at 754-55.
9Id. at 755-56.
98 Id. at 755.
99 Id. at 759.
100 Id.
101 The International Warfarin Pharmacogenetics Consortium, supra note 41,
at 758-59.
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pharmacogenetic algorithm was accurate for 26% of those patients
at the other end of the spectrum who needed 7 mg or more
warfarin per day, versus 9% accuracy for the clinical algorithm and
0% for the fixed dose approach. 0 2 Without the pharmacogenetic
testing, clinical modeling could not as accurately predict in which
dosing category a patient belonged. CMS objected to the tests
because they included incomplete data on whether patients
smoked, drank alcohol, or took vitamin K; limited study results to
patients with INR targets of 2-3; and contained incomplete
information on genotypes. 0 3
The studies that CMS evaluated had two to ten day time lags
from when the clinician ordered the pharmacogenetic tests to when
the clinician received the results.'04 CMS pointed out that warfarin
pharmacogenetic testing has little value for predicting outcomes
after a patient has been on warfarin for five days, but noted that
faster test result turnaround times would increase the tests' clinical
value.' A Medicare Evidence Development and Coverage
Advisory Committee ("MEDCAC") found that the evidence base
for pharmacogenetic testing is too immature.' 06
102 id.
103 CMS, supra note 88, at 10-11.
10 4 Id. at 4.
'os Id. at 19.
106 MEDCAC met to decide CMS coverage recommendations using
standardized genetic test evaluation tools. Id. at 12-13. The Centers for Disease
Control and Prevention's National Office of Public Health Genomics supports
using the Evaluation of Genetic Applications in Practice and Prevention working
group ("EGAPP"). Id. MEDCAC used an EGAPP-identified analytic and
clinical validity, clinical utility, and associated ethical, legal, and social
implications ("ACCE") framework to evaluate the data. Id.
MEDCAC addressed how confident they were "'that methodologically
rigorous evidence on the outcome is sufficient to infer whether or not diagnostic
genetic testing improves [three types of] patient centered health outcomes.' " Id.
at 12. They had high confidence for "' [d]irect patient-centered healthcare
outcome e.g., mortality, functional status, adverse events."' Id. at 13. The
voting member panelists gave an average of 4.8 out of a maximum of 5 votes.
All panelists gave a slightly lower average confidence level to all three types of
patient centered health outcomes. Id. They had slightly above average
confidence for "' [i]ndirect or intermediate healthcare outcomes e.g., changes in
laboratory test results such as hemoglobin or time to achieve a target value."'
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CMS ultimately decided that the evidence of warfarin
pharmacogenetic testing's clinical utility for improved patient
health outcomes is too insufficient to warrant Medicare
coverage.' Instead, Medicare patients who meet specific
criteria' can enroll in CMS approved prospective, randomized,
controlled studies."
b. Medco-Mayo Study
The Medco-Mayo study was not concluded in time to become a
part of the CMS analysis. The study examines warfarin
hospitalization rates for qualifying Medco Health Solutions'
("Medco") pharmaceutical benefits management ("PBM")
patients."0 From 2007-2009, researchers contacted Medco PBM
patients from fourty-nine states throughout the United States who
had filled new warfarin prescriptions during that time period."'
Id. The voting member panelists gave an average of 3.3 out of a maximum of 5
votes. Id. They had a little below average confidence for "'[c]hanges in
physician-directed patient management."' Id. at 12-13. The voting member
panelists gave an average of 2.1 out of a maximum of 5 votes. Id. at 13. They
found that a lower level of methodological rigor "would actually detract from
the ethical generation of evidence for genetic testing." Id at 13 (emphasis
removed). MEDCAC noted that when evaluating causes of death with an older
Medicare population, it is difficult to distinguish genetic causes from other
competing causes. MEDCAC did not explain their above findings other than
making a general statement that evidence for pharmacogenomic testing is
insufficient and that CMS should use its authority to gather more evidence. Id.
'OId. at 17-18.
'08 Medicare patients who have not previously had CYP2C9 and VKORCI
pharmacogenetic testing, have received warfarin for less than five days, and are
enrolled in a CMS approved study. Id. at 1-2.
109 Researchers would need to design studies that would distinguish the test's
evidence of clinical utility for warfarin dosing from bias, drug comorbidity
evidence, and other factors that affect warfarin dosing. Memorandum from Ctrs.
for Medicare & Medicaid Servs. on Pharmacogenomic Testing for Warfarin
Response (CAG-00400N) at 17-19 (Aug. 3, 2009), available at
http://www.cms.hhs.gov/mcd/ viewdecisionmemo.asp?id=224.
"o Epstein et al., supra note 66, at 2.
"' Participants were restricted to outpatients who filed new prescriptions, who
had not been on warfarin for the past six months, who were between ages 40-75,
who provided access to complete medical records, and who had physicians
willing to participate, and were followed for six months. Id
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Almost 900 patients ("pharmacogenetic patients") qualified on
all criteria. Seventy-five percent of doctors agreed to participate.
Three historical control groups were populated with outpatients on
warfarin who had not undergone CYP2C9/VKORC1
pharmacogenetic testing.112
The researchers took blood or buccal ("cheek swab") samples
from each pharmacogenetic patient. Mayo Clinic analyzed the
samples for CYP2C9 (combinations of *1, *2, *3 allele pairs) and
VKORC1 (GG, GA, or AA allele pairs)."' The researchers
electronically submitted each pharmacogenetic patient's
CYP2C9/VKORC1 genetic results to the patients' physician in a
report that also included one of four recommendations." 4
There was an 11-60 day lag time between when study patients
began taking the warfarin and when their physicians received the
warfarin pharmacogenetic results."' The study results showed a
direct correlation between progressively shorter turnaround times
and less patient risk of bleeds or thromboembolisms."' Despite
this time lag, when compared with the control groups, the
pharmacogenetic patients had 31% less hospitalization claims for
all causes and 28% less hospitalization claims for bleeds or
thromboembolisms."' These hospitalization differences were even
112 Id. at 2 and 6.
"1 Id. at 3.
114 1. The patient is likely to need an increase above the usual dose to
maintain a therapeutic INR.
2. The patient is likely to respond to the usual dose to maintain a
therapeutic INR.
3. The patient is likely to need a decrease from the usual dose to maintain
a therapeutic INR.
4. The patient is likely to need a decrease from the usual dose to maintain
a therapeutic INR and will need more frequent INR monitoring. If the genetic
results indicated that the patient fell into this category (36 out of 896 patients),
Mayo also contacted the physician by telephone with the recommendation.
McBane et al., supra note 48.
" This time frame included delays in patient contact until after the
prescription was filled, a visit to obtain samples and informed consent,
transporting samples to Mayo Clinic, and the testing-reporting process. Epstein
et al., supra note 66, at 6.
"
6 Id. at 6.
"
7 Id. at 4-5.
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more noteworthy when only considering hospitalizations occurring
after the study's physicians received the warfarin pharmacogenetic
results: 33% and 43%, respectively."'
Cardiologist Mandeep Mehra, speaking for the American
College of Cardiology, criticized the results because they were not
derived from a double blind study, and he felt that the controls
were inadequate."' However, all published reports indicate that
the other cardiologists who attended the presentation did not share
Dr. Mehra's concerns.120
3. Cost Considerations for Pharmacogenetic Testing
a. Actual Cost
FDA-approved warfarin pharmacogenetic tests have been
available since 2007 and are now obtainable at numerous
118 Id.
"l9 Turna Ray, Clinical Utility of PGx Warfarin Dosing Not Proven in Mayo-
Medco Study, Reviewer Concludes at Cardiology Meeting,
PHARMACOGENOMICS REPORTER (Mar. 17, 2010), available at
http://www.genomeweb.com/dxpgx/clinical-utility-pgx-guided-warfarin-dosing-
not-proven-mayo-medco-study-reviewer.
1201d.; See also Sue Hughes, Thrombosis: Warfarin Genotyping Reduces
Hospitalizations, THE HEART (Mar. 16, 2010), available at
http://www.theheart.org/article/1058617.do. Dr. Mehra's opposition to the
study may possibly have been colored by his employer's participation in an
ongoing Genotype-Guided Dosing of Warfarin Therapy study. Dr. Mehra is a
professor at the University of Maryland School of Medicine and is on staff at the
University of Maryland Medical Center ("UMMC"). UMMC is a participant in
the National Heart, Lung and Blood Institute, National Institutes of Health study
which is expected to conclude by 2011. University of Maryland Medical
Center, UMMC Has Been Selected as One of the Twelve Clinical Sites in the
Nation for a Genotype-Guided Clinical Trial for Warfarin/ Coumadin Therapy
("GGDWT"), 3 MOLECULAR PROFILE 2 (2009); Genotyped Guided Dosing of
Warfarin Clinical Trial Funding Opportunity---Central Laboratory RFP, UNIV.
OF PA. SCH. OF MED. & NAT'L HEART LUNG AND BLOOD INST.,
http://rt5.cceb.med.upenn.edu/warfdcc/WARF-1_pg5.html (last visited Apr. 8,
2010). That study will be much larger than many previous studies (1,200
patients). However, since its focus is the first month of dosage initiation, there
may not be much data on the prevention of serious bleeding events. Rena Conti
et al., Personalized Medicine and Genomics: Challenges and Opportunities in
Assessing Effectiveness, Cost-Effectiveness, and Future Research Priorities, 30
MED. DECISION MAKING 328, 333-34 (2010).
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laboratories. 121  Despite the hope that pharmacogenetic testing
would decrease health costs,122 costs for pharmacogenetic testing
have escalated along with other medical costs. The actual cost of a
warfarin pharmacogenetic test is much higher than the $250-$500
Genelex brand test estimate quoted in several research articles.123
Genelex 24 now charges $550 plus the cost of a blood draw.12 5 The
patient risks clots or hemorrhages during Genelex's mail-order test
process. After the patient receives the Genelex test kit, the patient
must still go to a laboratory to have blood drawn or self-
121 Laboratories offering CYP2C9/VKORC1 warfarin pharmacogenetic
testing include: Arup Laboratories (Salt Lake City, UT), Genelex (Seattle,
WA), Genomas Inc. (Newington, CT), Laboratory Corporation (throughout the
U.S.), Molecular Diagnostics Laboratories (Cincinnati, OH), PGXL
Laboratories (Louisville, KY), Quest Diagnostics (throughout the U.S.), and
Specialty Laboratories (Valencia, CA). Shin et al., supra note 65, at 633.
122 Andrew McWilliam et al., Health Care Savings from Personalizing
Medicine Using Genetic Testing: The Case of Warfarin, AEI-BROOKINGS JOINT
CTR. FOR REGULATORY STUDIES (Nov. 2006), http://reg-
markets.org/admin/authorpdfs/redirect-safely.php?fname=../pdffiles/WPO6-
23_topost.pdf.
123 Professors Shin, Kayser, and Langaee use a $250-$500 range estimate.
Shin et al., supra note 65, at 632 (citing Henry I. Bussey et al., Editorial:
Genetic Testing for Warfarin Dosing? Not Yet Ready for Prime Time, 28
PHARMACOTHERAPY 141, 142-43 (2008)). Professors Bussey, Hylek and
Wittkowsky, and Ms. Walker's article refers to "$250/test or $500 for both
tests." Bussey et al., supra, at 143 (citing McWilliam et al., supra note 122).
The original source of both the Jaekyu Shin et al., and Henry 1. Bussey et al.,
$250 estimate is a 2006 publication by Andrew McWilliam et al., of the AEI-
Brookings Joint Center for Regulatory Studies ("AEI-Brookings Studies").
McWilliam et al., supra note 122, at 10. The AEI-Brookings Studies authors'
$250 estimate was for a single CYP2C9 genetic test from Genelex, a direct to
consumer testing company. The $250 does not include Genelex's estimated
$100 for a blood draw, the cost for other CYP2C9 testing, or the cost for
VKORC 1 testing. Id. at 11.
124 Genelex uses the Luminex Molecular Diagnostics's Warfarin Tag-It PGx
Mutation Detection Kit to be used for investigational use only. Turna Ray,
Competition Heats Up in Warfarin Dx Market as New Tests Seek FDA OK,
PHARMACOGENOMICS REP. (Oct. 10, 2007), available at
http://www.genomeweb.com/dxpgx/competition-heats-warfarin-dx-market-new-
tests-seek-fda-ok [hereinafter Turna Ray (Oct. 10, 2007)].
125 Warfarin (Coumadin) Target Dose Safety Test (STAT 2C9 and VKORC1),
GENELEX, http://store.genelex.com/index.php?mainpage-product-info&
cPath=1 2&productsid=25 (last visited Apr. 9, 2010).
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administers the buccal swab, mail the blood or buccal swab to
Genelex, and wait for Genelex to post the results online five
business days later.126
The Mayo Clinic's list price for its Warfarin Sensitivity
Genotype test (CYO2C9*1 to CYO2C9*6 and VKORC1-
1639G>A) is $439.30. This price includes DNA sequencing, rapid
DNA extraction, and interpretation and review of the Warfarin
Sensitivity Genotype test results. There is no mention of a blood
draw cost which, presumably, would be extra.127 It is not an FDA-
approved test, but rather a Clinical Laboratory Improvement
Amendments ("CLIA") approved in-house test.128  Laboratory
Corporation of America ("LabCorp") charges $622 ($588 plus $34
blood draw) for its warfarin genetic test.129 It costs a laboratory
$60 for each FDA-approved TrimGen. The consumer's cost for
Q6 Id.
127 It tests for CYO2C9*2, CYO2C9*3, CYO2C9*4, CYO2C9*5,
CYO2C9*6, and VKORCl-1639G>A. Unit Code 89033: Warfarin Sensitivity,
Genotype, MAYO CLINIC, http://www.mayomedicallaboratories.com/test-
catalog/Clinical+and+1nterpretive/89033 and
http://www.mayomedicallaboratories.com/test-catalog/Fees+and+Coding/89033
(last visited Apr. 9, 2010).
128 Id. Mayo Clinic uses the Luminex Molecular Diagnostics's Warfarin Tag-
It PGx Mutation Detection Kit for investigational use only. Unit Code 89033:
Warfarin Sensitivity, Genotype, MAYO CLINIC,
http://www.mayomedicallaboratories.com/test-catalog/Performance/89033 (last
visited May 10, 2010). This is the same test that Genelex uses and that Mayo
Clinic used in the Medco-Mayo study. Ray (Oct. 10, 2007), supra note 124;
Epstein et al., supra note 66, at 3. CLIA gives CMS regulatory authority over
laboratories that overlap with FDA's authority. All laboratories that perform
patient testing must be CLIA certified. Peter M. Kazon, Regulatory Issues
Facing Genetic Testing, 3 J. HEALTH & LIFE Sci. L. 111, 118 (2010). The FDA
has recently exerted more control over this area. See Draft Guidance for
Industry, Clinical Laboratories, and FDA Staff-In Vitro Diagnostic
Multivariate Index Assays, FOOD & DRUG ADMIN. (July 26, 2007),
http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/
GuidanceDocuments/ucm071455.pdf.
129 Test Menu: Warfarin (P450 2C9 and VKOEC1), LAB. CORP. OF AM.,
https://www.labcorp.com/wps/portal/!ut/p/cl/04_SB8K8xLLM9MSSzPy8xBz9
CPOos hACzOQCMIwMLXyM3AyNjMycDU2dXQwN3M 1wkA7cKgwM
IPIGOICjgb6fR35uqn6kfpR5fKirSbChp6Wxgb-ru4GBkbmnj6elhb-hgZeBfoh-
QXZ2moujoilAyXfzzw!!/ (last visited Apr. 9, 2010); Telephone Interview with
Chris, Customer Service, Lab. Corp. of Am., Phoenix, AZ (Apr. 9, 2010).
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the TrimGen test is higher because the price includes the
laboratory mark-up'30 and the charge for the blood draw; whereas
the price of the FDA-approved AutoGenomics test is $100 per
variant for a total of $1,500.'
In summary, warfarin pharmacogenetic tests cost the patient
between $439 plus the price of a blood draw for the CLIA
approved Mayo Clinic and $1,500 for the FDA-approved
AutoGenomics tests. An insurer is more likely to cover a warfarin
pharmacogenetic test within this price range if the insurer
determines that the test's price is cost effective.'32
b. Cost Effectiveness Analysis
A cost effectiveness analysis of a warfarin pharmacogenetic
test should compare the cost and results of initiating warfarin
treatment guided by a pharmacogenetic test to the cost and results
of initiating warfarin treatment without a pharmacogenetic test.133
In 1996, the United States Public Health Service Panel on Cost-
Effectiveness in Health and Medicine recommended the quality
adjusted life year ("QALY") as a standardized measure for health
outcomes.'34
130 Turna Ray, TrimGen to Debut New Warfarin-Dosing IVD in 'Near Future'
as FDA Clearance Nears, PHARMACOGENOMICS REP. (Sept. 10, 2008),
available at
http://webcache.googleusercontent.com/search?q=cache:X 3TSHelKNYJ:www.
genomeweb.com/dxpgx/trimgen-debut-new-warfarin-dosing-ivd-near-future-
fda-clearance-nears+trimgen+%22warfarin+genotyping%22+cost+OR+price+
OR+%24&cd=2&hl=en&ct-clnk&gl=us.
13' The AutoGenomics warfarin pharmacogenomic test checks for fifteen
variants which it claims is more than any other company; Biosciences and
Genelex: six variants; Harvard Medical and Nanosphere: four variants;
Clinical Data, Kimball Genetics, and Laboratory Corporation of America: three
variants. Ray (Oct. 10, 2007), supra note 124.
132 See infra Part II.B.3.c.
Robert J. Milligan, Symposium: Law and the New Era of Personalized
Medicine, Coverage and Reimbursement for Pharmacogenomic Testing, 48
JURIMETRICS J. 137, 157 (2008).
1 Milton C. Weinstein et al., Recommendations of the Panel on Cost-
Effectiveness in Health and Medicine, 276 J. AM. MED. Ass'N 1253, 1254
(1996). There are three parts to a QALY measurement: the cost of the health
intervention, the difference between a person's health with and without the
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A QALY of below $50,000 is considered cost-effective.1 5 In
order to obtain a QALY of less than $50,000, physician Mark
Eckman and colleagues calculated that a warfarin pharmacogenetic
test would have to cost less than $200, have a one day turnaround
time, and prevent 32% of major bleeds." 6 The twenty-four hour
turnaround time is plausible with the FDA-approved tests.' Even
with an in-house, CLIA approved test, Mayo Clinic has established
a less than twenty-four hour turnaround time from the time its
clinicians order the warfarin pharmacogenetic tests to the time that
the clinician receives the pharmacogenetic test results along with
recommendations for increasing, maintaining, or decreasing
warfarin dosages."' This turnaround time goes a long way toward
resolving the CMS Decision's clinical validity concerns with two-
to ten-day turnaround times. However, given that the
health intervention, and the number of years that the suboptimal health condition
is expected to last. Id. at 1256-58.
For instance, part one of the Qualy measurement would be $1,000, if that is
the cost of a health intervention. For part two, a number between zero and one
is assigned that represents the quality of life based on the state of a person's
health. Milligan, supra note 133, at 158. A person's optimal health has a
quality number of one; a person's death has a quality number of zero. Weinstein
et al., supra note 134, at 1256. If a health intervention improves a patient's
quality of life from .4 to 1, then the difference in the quality, .6, is part two of
the QALY measurement. See Weinstein et al., supra note 134, at 159. Part
three is the length of the health condition. A chronic condition is measured by
the number of years remaining for that person's life expectancy. Id. at 158. In
this example, assuming a 20 year life expectancy for a chronic condition, the
QALY would be $12,000: ($1,000 health intervention cost) - (.6 quality of life)
(20 years).
"3 Milligan, supra note 133, at 159. Although the $50,000 breakpoint was
established in 1982, it is still widely used. Id. at 159, n. 185.
136 Mark H. Eckman et al., Cost-Effectiveness of Using Pharmacogenetic
Information in Warfarin Dosing for Patients With Nonvalvular Atrial
Fibrillation, 150 ANNALS OF INTERNAL MED. 73, 78 (2009).
'3 Nanosphere's test takes 45 to 90 minutes to get results. Even the more
complex AutoGenomics system has same day results. Ray (Oct. 10, 2007),
supra note 124.
138 Once a patient in the warfarin pharmacogenetic testing group enrolled in
the study, the patient's physician only had to prescribe one warfarin dose
without knowing the patient's genetic information. McBane et al., supra note
48.
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pharmacogenetic test is unlikely to cost less than $500,139 that $200
QALY scenario is unlikely.
Clinicians may decide against using warfarin pharmacogenetic
testing to determine initial warfarin dosing because of the above
clinical utility and cost effectiveness analyses shortcomings.
However, the Warfarin Consortium and Medco-Mayo studies show
that when clinicians only take a patient's phenotypical attributes
into account (such as standard starting dosages, age, "race", and
medication interactions), the net result is that they accept status
quo warfarin dosing for their patients that are replete with high
ADEs.140 Neither clinical utility nor cost effectiveness analyses
address how a clinician can effectively predict who the few high
risk patients are, as identified in the Medco-Mayo study,14 ' without
warfarin pharmacogenetic test results.
c. Private Insurance Coverage
Private insurers often follow Medicare's lead on coverage
issues, sometimes paying a percentage of what Medicare
charges.'42 Since Medicare has decided not to cover warfarin
pharmacogenetic tests,'4 3 that may eliminate coverage by a number
of private insurers. Unlike Medicare, private insurers also evaluate
the cost effectiveness of a pharmacogenetic test in order to
determine whether or not the policy will cover it.'44 The current
private insurance tally for CYP2C9 and VKORC1
pharmacogenetic testing is as follows: five have determined that
the testing is investigational or experimental because there is not
sufficient clinical validity or utility information,"' and one covers
"9 See supra notes 121-32 and accompanying text.
140 See supra notes 95-101 and 110-18, and accompanying text.
141 The Medco-Mayo study found that 4% of its patient-subjects who had
pharmacogenetic testing had high sensitivity to warfarin and 2.6% more had
very high sensitivity, for a total of 6.6%. The difference in warfarin dosage was
.5-2 mg in these two groups versus 5-7 mg for those patients who had normal
sensitivity. See supra notes 63-64 and accompanying text.
142 Milligan, supra note 133, at 155.
143 See supra notes 106-09 and accompanying text.
'4 Milligan, supra note 133, at 155.
145 They are Aetna, Health Net, Humana, WellPoint BlueCross BlueShield,
and CIGNA. Clinical Policy Bulletin: Pharmacogenetic Testing (Number:
0715), AETNA, http://www.aetna.com/cpb/medical/data/700_799/0715.html (last
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it as an option.4 6 Without Medicare and most private insurance
coverage, patients may choose to forego clinician-recommended
pharmacogenetic testing.'47 Clinicians who weigh patient cost
concerns along with conflicting CMS and FDA 2010 warfarin
label recommendations may hesitate to recommend warfarin
pharmacogenetic testing.
III. LEGAL IMPETUS FOR WARFARIN PHARMACOGENETIC
TESTING
A. FDA's Labeling Requirements as Applied to Warfarin
1. FDA's Decision to Reconsider its 2007 Coumadin Label
In August of 2007, the FDA revised the Coumadin label to
include a discussion of CYP2C9 and VKORC1 pharmacogenetic
factors without making a clear recommendation for
pharmacogenetic testing.14 At the time of that 2007 revision, the
FDA had not approved any CYP2C9/VKORC1 pharmacogenetic
visited Sept. 3, 2010); National Medical Policy: Pharmacogenetic Testing
(Policy Number: NMP348), HEALTHNET, 1,
https://www.healthnet.com/static/general/unprotected/pdfs/national/policies/phar
macogenetic testing feb 10.pdf (last updated Feb. 2010); Pharmacogenomics
(Pharmacogenetics): Medical Coverage Policy (Policy Number: CPD-0466-
014), HUMANA, 8-9 (2010), http://apps.humana.com/tad/tad new/
Search.aspx?criteria=pharmacogenomics&searchtype-freetext; Genetic Testing
for Warfarin Sensitivity (Medical Policy: 02.01.33), WELLMARK BLUECROSS
BLUESHIELD, https://www.wellmark.com/Provider/
MedPoliciesAndAuthorizations/MedicalPolicies/policies/ WarfarinSensitivity
PrinterFriendly.aspx (renewed Sept. 2010); CIGNA Medical Coverage Policy-
Subject: Pharmacogenetic Testing for Warfarin Metabolism (Coverage Policy
Number 0484), CIGNA, 1 (July 15, 2010), http://stage.cigna.com/
customer care/healthcarejprofessionaUcoveragepositions/medical/mm 0484 c
overagepositioncriteria_pharmacogenetic testing for warfarin metabolism.pdf.
CIGNA covered CYP2C9 and VKORC1 pharmacogenetic testing for medical
necessity following its November 2007 review, but reversed its coverage
decision after its July 2010 review. CIGNA, supra.
146 APWU Health Plan is for postal employees, federal employees, and federal
retirees. United Healthcare administers the plan. Consumer Driven Option,
APWU HEALTH PLAN (2010),
http://www.opm.gov/insure/health/planinfo/201 0/brochures/71-004.pdf
147 Conti et al., supra note 120, at 6.
148 BRISTOL-MYERS SQUIBB CO. (2007), supra note 7, at 25
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tests. That soon changed in September of 2007 when the FDA
approved the first of five such test systems.149
Against this backdrop of FDA-approved CYP2C9/VKORC1
pharmacogenetic tests and conflicting clinical utility findings, the
FDA evaluated the 2009 Warfarin Consortium study.' Unlike
CMS, the FDA's Center for Drug Evaluation and Research
("CDER") Director Woodcock and Office of Clinical
Pharmacology ("OCP") Director Lesko supported the Warfarin
Consortium study's conclusions.'"' The study evaluated the
efficacy of pharmacogenetic testing for predicting warfarin
dosing, 5 2 finding that 46% of warfarin patients benefited from the
Warfarin Consortium study's pharmacogenetic dosing algorithm.'
FDA officials Woodcock and Lesko opined that pharmacogenetic
testing is the only way to determine in advance which 46% are
likely to benefit from warfarin dosing based on pharmacogenetic
factors.15 4
2. 2007 and 2010 Coumadin Label Similarities
a. Pharmacogenomic Studies
In January of 2010, the FDA revised the 2007 Coumadin
label.' All of the studies relied upon in the 2007 label'5 6 are
similarly relied upon in the 2010 label.'
In 2007, under the Clinical Pharmacology heading, the FDA
added a Pharmacogenomics subheading that did not exist in prior
warfarin labels.' That subheading and all of its contents remain
149 See supra notes 75-77 and accompanying text.
Iso See supra notes 94-98 and accompanying text.
'51 Woodcock & Lesko, supra note 80, at 811-13.
152 The International Warfarin Pharmacogenetics Consortium, supra note 35,
at 753-65.
15 See supra notes 99-103 and accompanying text for a discussion of the
study.
154 Id.
1 BRISTOL-MYERS SQUIBB CO. (2010), supra note 6, at 1.
56 BRISTOL-MYERS SQUIBB Co. (2007), supra note 7, at 4, 28-30.
1 BRISTOL-MYERS SQUIBB Co. (2010), supra note 6, at 5, 29-31.
15' BRISTOL-MYERS SQUIBB Co. (2007), supra note 7, at 4.
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in the 2010 revision. 5 9 In accordance with Title 21 of the Code of
Federal Regulations, section 201.57(c)(2)(i)(B), both labels discuss
the studies' results regarding the variations in the CYP2C9 and
VKORC1 genes and other subgroup variables (race, sex, age,
etc.). 160
b. Pharmacogenetic Testing Issues
21 C.F.R. § 201.57(c)(2)(i)(C) requires that a drug label state
the "identity" of specific tests "necessary" for monitoring or
selecting patients that need the drug. Both of the recent label
revisions stop short of identifying by name the specific
pharmacogenetic tests that a clinician might order to provide the
above warfarin pharmacogenetic data. At least one scholar has
argued that this regulation requires FDA to name a
pharmacogenetic test within the label.' 6 1
Although including the name of the test would clearly provide
more guidance to the clinician prescriber, it is less clear that the
FDA has the authority to do so. If the FDA requires that
Manufacturer A (a drug company that manufactures warfarin)
cross-label to a product produced by Manufacturer B (a device
company that manufactures CYP2C9/VKORC1 pharmacogenetic
tests), then Manufacturer A would have to make frequent, costly
updates as new pharmacogenetic tests become available.'62
Furthermore, such cross-labeling has the potential to make
Manufacturer A liable for a defect in Manufacturer B's product.163
Given such burdensome results, this author maintains that the FDA
159 BRISTOL-MYERS SQUIBB CO. (2010), supra note 6, at 5-6; BRISTOL-
MYERS SQUIBB Co. (2007), supra note 7, at 4-5.
160 BRISTOL-MYERS SQUIBB CO. (2010), supra note 6, at 3-5 and 26-27;
BRISTOL-MYERS SQUIBB Co. (2007), supra note 7, at 2-5 and 25. The labels
refer to a meta-analysis of nine studies with 2775 patients that review CYP2C9
*1, *2, and *3 genetic alleles. BRISTOL-MYERS SQUIBB Co. (2007), supra note
7, at 4; BRISTOL-MYERS SQUIBB CO. (2010), supra note 6, at 5.
16 Mollie Roth, Predictive Health Technologies: The Warfarin Revised
Package Insert: Is The Information in the Label "Too Thin"?, 9 HOUS. J.
HEALTH L. & POL'Y 279, 281 (2009).
162 Barbara J. Evans, What Will It Take to Reap the Clinical Benefits of
Pharmacogenomics?, 61 FOOD DRUG L. J. 753, 781, 786 (2006).
163 Id. at 786.
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did not intend 21 C.F.R. § 201.57(c)(2)(i)(C) to require cross-label
branding.
Even if the FDA only specifies the type of warfarin
pharmacogenetic test, its recommendation will quickly become
outdated as warfarin pharmacogenetic test manufacturers create
new types of tests.'" This would still probably require the drug
manufacturer to make frequent, costly label updates, but it would
seem to satisfy 21 C.F.R. § 201.57(c)(2)(i)(C), as well as provide
the clinician with some guidance."'
3. 2007 and 2010 Coumadin Label Distinctions
a. Clinical Pharmacology
Under the Clinical Pharmacology heading, the Excretion
subheading follows the Pharmacogenomics subheading in the 2007
label, but precedes it in the 2010 version.'66 Other than a different
subheading order, the two label versions include the same Clinical
Pharmacology material.'"' In fact, the content of the two labels are
virtually identical except for differing provisions under one Dosage
and Administration subheading: Initial Dosing.168
b. Dosage Recommendations
The Code of Federal Regulations chapter 21,
§ 201.57(c)(2)(i)(B) requires that a drug's label include available
evidence of the drug's effectiveness and safety in a subgroup of the
larger population. The rule cites effectiveness for a specific age
group as an example of a population subgroup' 9 . If effectiveness
and safety evidence only supports the drug's use within select
6 Id.
165 As pointed out by Professor Roth, the FDA has precedent for generally
mentioning the availability of pharmacogenetic testing with mercaptopunine in
the 2003 label, even when that pharmacogenetic testing is not FDA approved.
Roth, supra note 162, at 281-82.
16 BRISTOL-MYERS SQUIBB Co. (2007), supra note 7, at 4-5; BRISTOL-
MYERS SQUIBB CO. (2010), supra note 6, at 5-6.
i6 BRISTOL-MYERS SQUIBB CO. (2007), supra note 7, at 2-6; BRISTOL-
MYERS SQUIBB CO. (2010), supra note 6, at 2-6.
168 BRISTOL-MYERS SQUIBB Co. (2007), supra note 7, at 24--25; BRISTOL-
MYERS SQUIBB CO. (2010), supra note 6, at 26-27.
16921 C.F.R. § 201.57(c)(2)(i)(B) (2010).
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population subgroups, the label must include evidence of the
drug's "limitations of usefulness."70
Warfarin is not effective and safe unless dosing considerations
include its differing effects on myriad population subgroups."'
Among them, mixtures of racial and ethnic subgroups are difficult
to quantify. 172 Warfarin pharmacogenetic testing objectively
identifies genetic distinctions in warfarin sensitivity that are
influenced by racial and ethnic differences, but that are not easily
discernable through subjective racial and ethnic phenotypes."'
Thus, 21 C.F.R. § 201.57(c)(2)(i)(B) requires that the warfarin
drug label include evidence of warfarin's "limitations of
usefulness." The 2010 label, and to a lesser extent, the 2007 label,
addresses the requisite usefulness limitations under Dosage and
Administration.174
21 C.F.R. § 201.100(b)(2) requires that a prescription drug
label state either the drug's "recommended" dosage or its "usual"
dosage.'75  21 C.F.R. § 201.57(c)(3)(i) clarifies that under the
Dosage and Administration heading, the label must state what the
"recommended dose" is including dosage modifications for
"special patient populations" such as "in groups defined by genetic
characteristics."176
In both label versions under Dosage and Administration, the
first paragraph ends with the following statement in bold type:
"The best available information supports the following
recommendations for dosing of COUMADIN."' This is
followed by information under five subheadings of disease states
170 Id.
17' 21 C.F.R. § 201.57(c)(3)(C) (2010) requires that the label state appropriate
dosages for each subpopulation.
172 See supra notes 48, 62-64, and 103 and accompanying text.
1 Id.
174 BRISTOL-MYERS SQUIBB Co. (2007), supra note 7, at 22-27; BRISTOL-
MYERS SQUIBB Co. (2010), supra note 6, at 24-29.
1 21 C.F.R. § 201.100(b)(2) (2010).
17 21 C.F.R. § 201.57(c)(3)(i)(H) (2010).
" BRISTOL-MYERS SQUIBB CO. (2007), supra note 7, at 23; BRISTOL-MYERS
SQUIBB Co. (2010), supra note 6, at 24.
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or medical conditions."' Under each of those subheadings, the
label does not state specific dosage recommendations. Rather,
each label recommends dosage adjustments to achieve
recommended INR ranges.179  The sixth Dosage and
Administration subheading is Initial Dosing,'s the only category
containing substantial differences in content between the 2007 and
2010 labels.
Under Initial Dosing, the 2007 label recommends that the
clinician initiate Coumadin at two to five milligrams daily as
adjusted by PT/INR results.'"' In contrast to that dosage
recommendation, the 2007 revision suggests considering the
following changes for special populations:
The lower initiation doses should be considered for patients
with certain genetic variations in CYP2C9 and VKORC1
enzymes as well as for elderly and/or debilitated patients
and patients with potential to exhibit greater than expected
PT/INR responses to COUMADIN.... 82
Unlike the 2007 label, the 2010 revision's Initial Dosing
subheading does not specifically state a "recommended" initial
Coumadin dose.' The latter label discusses several factors that
"influence" the dose needed to maintain (not to initiate) PT/INR
target results: clinical (a patient's weight, age, sex, race,
comorbidities, and concomitant medications) and genetic factors
s BRISTOL-MYERS SQUIBB Co. (2007), supra note 7, at 23-24; BRISTOL-
MYERS SQUIBB Co. (2010), supra note 6, at 24-26.
179 Bristol-Myers Squibb Co. (2007), supra note 7, at 23-24; Bristol-Myers
Squibb Co. (2010), supra note 6, at 24-26.
18o BRISTOL-MYERS SQUIBB Co. (2007), supra note 7, at 24-25; BRISTOL-
MYERS SQUIBB Co. (2010), supra note 6, at 26.
BRISTOL-MYERS SQUIBB Co. (2007), supra note 7, at 25. In order to assess
the amount of coagulation in a warfarin patient's blood, health care workers
look at PT because it is "sensitive to prothrombin" as well as two other blood
factors, VII and X, that have to do with clotting. Id. PT prolongation is
measured using the internationalized ratio ("INR"). Alexander G.G. Turpie,
Vitamin K Antagonists: Benefits and Limitations, THROMBOSIS ADVISOR,
http://www.thrombosisadviser.com/scripts/pages/en/current-treatments/
anticoagulants/vitamin-k-antagonists/index.php (last visited May 4, 2010).
182 BRISTOL-MYERS SQUIBB CO. (2007), supra note 7, at 25.
18 BRISTOL-MYERS SQUIBB Co. (2010), supra note 6, at 26-27.
135
N.C. J.L. & TECH.
(CYP2C9/VKORC1 genotypes), acknowledging the existence of
other unknown variables that affect dosing.'" The new label does
not repeat the 2007 label's recommendation of starting initial
dosing at two to five milligrams daily. Instead, it evinces a non-
mandatory preference for pharmacogenetic testing: "[i]f the
patient's CYP2C9 and VKORC1 genotypes are not known, the
initial dose of COUMADIN is usually 2 to 5 mg per day",' 5 which
may be a reference to the 21 C.F.R. § 201(b)(2) "usual dosage."
Under the Initial Dosing subheading, the current label also adds
a dosing chart, reprinted in Table 2 below, that incorporates the
known warfarin genetic factors."' Despite the 21 C.F.R.
§ 201.57(c)(3)(i) requirement for a "recommended dose" under the
label heading, Dosage and Administration, 18 7 the dosing chart
contains expected doses, but does not specify that the FDA
recommends these doses.'
Table 2: Range ofExpected Therapeutic Warfarin Doses Based on
CYP2C9 and VKORCl Genotypest
VKORC1 CYP2C9
*1/*1 *1/*2 *1/*3 *2/*2 *2/*3 *3/*3
AA 3-4 mg 3-4 mg ( .
Ranges are derived from multiple published clinical studies. Other clinical
factors (e.g., age, race, body weight, sex, concomitant medications, and
comorbidities) are generally accounted for along with genotype in the ranges
expressed in the table. VKORC1 -1639 G>A (rs9923231) variant is used in this
184 Id. at 26. However, the 2010 label later states that a patient's clinical
factors are generally accounted for in their dosage chart that adjusts dosages
solely based on a patient's genetic factors, obviating the need to consider those
clinical factors if the clinician obtains the patient's CYP2C9 and VKORC1
genotypes. Id. at 27.
185 Id (emphasis added).
186 Id at 27.
187 Id at 24-29.
1 BRISTOL-MYERS SQUIBB CO. (2010), supra note 6, at 26-27.
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table. Other co-inherited VKORC 1 variants may also be important determinants
of warfarin dose. Patients with CYP2C9 *1/*3, *2/*2, *2/*3, and *3/*3 may
require more prolonged time (>2 to 4 weeks) to achieve maximum INR effect
for a given dosage regimen.1 89
On its surface, the 2010 label does not appear to be in
compliance with the 21 C.F.R. § 201.57(c)(3)(i) requirement of a
"recommended dose" under Dosage and Administration. Though
there are recommendations for INR levels and a recommendation
against loading doses, the Initial Dosing verbiage contains no
specific recommendations for the actual doses.' 90
It is an axiom of administrative law that "agencies are entitled
to a presumption that they 'act properly and according to law." 9
Given this assumption, it is appropriate to presume that the FDA
intended the 2010 label to comply with the C.F.R. dosage
recommendation requirement. In order to do so, the FDA must
have intended its reference to "the following recommendations
for dosing of COUMADIN"' 92 to apply to the content of all of the
Dosage and Administration subheadings following that bolded
statement. Therefore, a reasonable construction of the FDA's 2010
statement of preference for initial dosing based on the "patient's
CYP2C9 and VKORC1 genotypes", the FDA's dosing chart, and
the 2-5 mg genotype starting dose when the genotype is unknown
is that those are the FDA's initial dosage recommendations.
Although the FDA gave allowances for situations where the
genotype is unknown, it indicated a preference for using the
pharmacogenetic information, stating that "when available, [it] can
assist in selection of the starting dose."'9 3 A necessary corollary to
this dosing recommendation preference is that the FDA must also
be recommending pharmacogenetic testing, though not the branded
name of that test, to discover CYP2C9 and VKORC1 genotypes
189 Id. at 27.
'90 Id. at 26-27.
191 Kohli v. Gonzales, 473 F.3d 1061, 1068 (9th Cir. 2007) (quoting FCC v.
Schreiber, 381 U.S. 279, 296 (1965)).
192 BRISTOL-MYERS SQUIBB Co. (2010), supra note 6, at 24.
'9' Id. at 26.
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because those genotypes are integral to the FDA's dosing
recommendations. 9 4
B. Liability Issues Arising from 2010 Coumadin Label
The PPACA authorizes the immediate establishment of an
independent, non-government, Washington, D.C. non-profit
corporation known as the Patient-Centered Outcomes Research
Institute ("Institute")."' The Institute will compare "health
outcomes and the clinical effectiveness, risks, and benefits of 2 or
more medical treatments, services, and items""' taking into
account various subpopulations, such as individuals with different
"genetic and molecular sub-types.""' If "feasible and
appropriate," the studies must include members of those
subpopulations.'98 The Institute's governing board must identify
research priorities; establish a research project agenda; and carry
out that agenda by assessing past and future research, conducting
primary research, and contracting for research.'9 9
The Institute's governing board may decide to grant research
priority to establish the clinical effectiveness of warfarin
194 The 2007 label contains the same language as the 2010 label regarding "the
following recommendations for dosing of Coumadin." BRISTOL-MYERS SQUIBB
Co. (2007), supra note 7, at 23. Two pharmacy professors at the University of
California-San Diego and a genetics professor at the University of Florida
College of Pharmacy-Gainesville agree that the 2007 Coumadin label also
recommends pharmacogenetic testing. Shin et al., supra note 65, at 630.
195 Patient Protection and Affordable Care Act of 2010, Pub. L. 11-148, 124
Stat. 119 § 6301(a) (2010) (amending Social Security Act § 1181(b)(l)-(2),
(d)(2)(A)(i)), 42 U.S.C. § 1320e(b)(1)-(2), and (d)(2)(A)(i)) (2006)). It is
unclear who has the authority to establish this Institute; though, the Comptroller
General of the United States has the responsibility to appoint its Governing
Board and Methodology Committee members. Social Security Act § 1181
(d)(6), (f)(1)(C) (as amended by PPACA § 6301(a) (2010)).
196 Social Security Act § 1181(a)(2)(A) (as amended by PPACA § 6301(a)
(2010)).
'
9 Id. § (d)(2)(D).
198 Id. The United States Comptroller General must appoint a governing
board and methodological committee whose members will include
patients/consumers, a federal agency/program, National Institutes of Health,
Agency for Healthcare Research and Quality, health care workers, and private
payers. Id. § (d).
'99 Id. § (d)(1)-(2).
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pharmacogenetic testing given the disparity among the CMS study,
the Medco-Mayo study, and the FDA's 2010 Coumadin label
recommendations. This possibility is even more likely if the
Comptroller General includes an FDA member as its representative
of "a Federal health program or agency" on the governing board.200
Since any such review or study must incorporate patients in
subpopulations with a propensity for warfarin genetic
susceptibilities, such as those of African and Asian ethnicities,2 0 '
the results ought to contain more of the genetic outliers who
require substantially increased or decreased warfarin in initial
dosing.202
An independent Institute analysis is more likely to result in a
decision favoring warfarin pharmacogenetic sensitivity testing.
However, it will take at least two years after the Institute is
established before its governing board can initiate such an
analysis.203 In the meantime, manufacturers, pharmacists, health
200 1d. § (f)(6).
201 See supra notes 48, 62-64, 103, and accompanying text.
202 See supra notes 80-83, 151-54 and accompanying text for a discussion of
these outliers as identified by FDA Center Directors Woodcock and Lesko.
203 To begin with, the Institute must be created as a non-government,
Washington, D.C., non-profit corporation known as the "Patient-Centered
Outcomes Research Institute." Patient Protection and Affordable Care Act of
2010, Pub. L. 11-148, 124 Stat. 119 § 6301(a) (2010) (amending Social Security
Act § 1181(b)(i)-(2)), 42 U.S.C. § 1320e(b)(1)-(2) (2006)). To date, the
District of Columbia has not posted any record of a non-profit corporation
named Patient-Centered Outcomes Research Institute. D.C., DEPT. OF
CONSUMER AND REGULATORY AFFAIRS, CORPS Div.,
http://mblr.dc.gov/corp/reservation/
results.asp?algorithm=mtphnl&corptype=2&rec limit=50&searchtype=1 &cl
p_mod=2&keywords=Patient&submit-Continue+to+Step+3+%3E%3E (last
visited Nov. 23, 2010). Once the Institute is established, the Comptroller
General of the United States has eighteen months to appoint a methodology
committee, have that committee meet and develop methodology standards for
comparative clinical effectiveness research, and receive those standards. Patient
Protection and Affordable Care Act of 2010, Pub. L. 11-148, 124 Stat. 119
§ 6301(a) (2010) (amending Social Security Act § 1181(d)(6)(C)), 42 U.S.C.
§ 1320e(d)(6)(C) (2006). This must be followed by a forty-five to sixty day
public comment period. Id. § (h)(1). After which, the Institute must establish
research priorities and, establish a research project agenda, followed by another
forty-five to sixty day public comment period before it can begin any analysis.
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care institutions, physicians, and other health care workers must
navigate through an uncertain legal minefield.
1. Manufacturer Product Liability-Causation Issues
Under product liability law, a prescription drug manufacturer is
liable if it sells or distributes a defective prescription, the defect
causes a person harm, and at the time of the sale or distribution any
of the following occur:204
* The prescription drug manufacturer does not give
reasonable instructions or warnings of foreseeable risks of
harm to:
o The health care provider (including the
prescriber), if the health care provider would have
been able to reduce those risks at the time of the
sale or distribution had the health care provider
received the manufacturer's instructions or
warnings;205 or
o The patient, if the manufacturer had reason
to know that the health care provider would have
been able to reduce those risks had the health care
provider received the manufacturer's instructions or
warnings;206
* A reasonable health care provider, knowing the
foreseeable treatment risks and benefits, would not have
prescribed the drug "for any class of patients; or"207
* The defect results from the product's design.20 8
In each of the above instances, the manufacturer is liable
regardless of whether the manufacturer exercised reasonable care,
a strict liability standard.209
a. Learned Intermediary Defense
204 RESTATEMENT (THIRD) OF TORTS: PROD. LIAB. § 6(a)-(b) (1998).
205 Id. § 6(b)(3), (d)(1).
2 06 1d. § 6(b)(3), (d)(2).
207 Id. § 6(b)(2), (c).
208 Id. § 6(a)-(b) (1), 2(a).209 1d §§ 2, 6.
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The learned intermediary doctrine limits a prescription drug
manufacturer's liability to the patient by warning the clinician, the
learned intermediary, of the drug's risks to the patient.2 10 The
premise of this defense is that the manufacturer-provided drug
information is directed to the health care clinician who acts as the
intermediary between the manufacturer and the patient to avoid
patient injury.2 11 Under this theory, if a warfarin manufacturer
places sufficient patient genetic-susceptibility information on the
warfarin prescription label, the manufacturer has fulfilled its
obligation to warn the patient.
In 1966, the judge in Sterling Drug v. Cornish first gave the
learned intermediary doctrine its name.212 Since that time, courts
have retreated from the notion that manufacturers have no
obligation to provide pertinent medication information directly to
potential patients.213 Courts have increasingly granted patients the
right to participate in decisions regarding their own medical care.214
Just as it is no longer solely within physicians' discretion to decide
whether patients should have access to their own medical
information, sometimes it is no longer within manufacturers' sole
discretion to only provide the learned intermediaries with patient
medication information.215 Over the last fifteen years,
manufacturers have targeted patients through direct to consumer
("DTC") prescription drug advertising. This DTC advertising
certainly seems to obviate the premise behind the Sterling Drug v.
Cornish learned intermediary doctrine that the doctor is acting as
the intermediary.2 16 At least two state supreme courts agree with
this trend; in 2007, West Virginia followed New Jersey's lead in
210 Sterling Drug, Inc. v. Cornish, 370 F.2d 82, 85 (8th Cir. 1966).
211 James Ottavio Castagnera & Richard Ryan Gerner, The Gradual
Enfeeblement of the Learned Intermediary Rule and the Argument in Favor of
Abandoning It Entirely, 36 TORT & INS. L. J. 119, 123 (2000).
212 Sterling, 370 F.2d at 85.
213 Castagnera & Gerner, supra note 211, at 123.
2 14 I[d.
215 Id.
216 Id.; Teresa Kelton, Pharmacogenomics: The Re-Discovery of the Concept
of Tailored Drug Therapy and Personalized Medicine, 19 HEALTH LAWYER 1, 8
(2007); Mark A. Rothstein, Liability Issues in Pharmacogenomics, 66 LA. L.
REV. 117, 120 (2005).
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eliminating the defense.217 In Perez v. Wyeth Laboratories, the
court ruled that the New Jersey statute that codifies the learned
intermediary doctrine "does not confer on pharmaceutical
manufacturers a license to mislead or deceive consumers when
those manufacturers elect to exercise their right to advertise their
product directly to such consumers."2"8
However, one of the reasons that the learned intermediary
doctrine has had such staying power is that it recognizes that the
real issue with manufacturer liability is causation. It is more
difficult to prove that the manufacturer's actions are the direct
cause of the patient's injuries when the health care provider's
treatment decision adds an intervening cause for those injuries.
This is especially true when the clinician lawfully prescribes a
medication off-label, either for a different use or for a different
dosage than recommended on the prescription drug label. 219 The
manufacturer makes safety and efficacy claims based on clinical
study results with the backing of FDA-approved uses and
dosages. 2 0 The clinician's intervening off-label prescribing breaks
the chain of causation between the acts of a prescription drug
manufacturer and the patients' injuries. Warfarin-injured patients
will have difficulty reaching into a warfarin manufacturer's deep
pockets if the patients' clinicians prescribe warfarin off-label and
without pharmacogenetic testing (unless a manufacturer illegally
217 State ex rel. Johnson & Johnson Corp. v. Karl, 647 S.E.2d 899, 914 (W.
Va. 2007).
218 Perez v. Wyeth Laboratories, 734 A.2d 1245, 1264 (N.J. 1999).
219 Clinician off-label use of prescription drugs is lawful. However, its off-
label promotion can violate several federal laws. The FDA usually regulates
manufacturers' off-label promotions of prescription drugs under federal
misbranding statutes. For a more in-depth discussion of FDA's authority in this
area, see Good Reprint Practices for the Distribution of Medical Journal
Articles and Medical or Scientific Reference Publications on Unapproved New
Uses of Approved Drugs and Approved or Cleared Medical Devices, FOOD &
DRUG ADMIN. (Jan. 2009), http://www.fda.gov/RegulatoryInformation/
Guidances/ucml25126.htm. The safe harbor provision of the Food and Drug
Administration Modernization Act ("FDAMA") relied upon in Washington
Legal Found. v. Henney, 128 F. Supp. 2d 11 (D.C. 2000) has since been
repealed. Without the FDAMA safe harbor provision, the legal effect of FDA's
current guidance on Good Reprint Practices is murky.220 d
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promotes off-label prescribing,2 21 or warfarin is not reasonably safe
because of unclear or inadequate instructions 222).
b. Specific Causation Defense
Despite movement toward more patient health care autonomy,
the few plaintiffs who have brought genetic susceptibility lawsuits
against prescription drug manufacturers have had little success.
Plaintiffs have been stymied by their failure to prove specific
causal connections between their injuries and genetic susceptibility
to the manufacturers' product.
Easter v. Aventis Pasteur, Inc.223 is an illustrative example.
The plaintiffs alleged that the defendant manufacturer's
thimerosal-containing224 vaccine caused their autistic son's
numerous comorbid neurological conditions. 225  The Easters
conceded that they could not prove that thimerosal caused their
son, Jordan's, autism because he does not fit the genetic profile for
alleged thimerosal susceptibility. 226  The Easters sought to have
their expert testify that there is a correlation between Jordon's
neurological conditions and his combined thimerosal exposure.227
The court ruled that a plaintiff must prove both general and
specific causation. 228 General causation in the Easter case would
have been present if the plaintiff had proved that thimerosal caused
the same type of injuries claimed by the plaintiff.229 Specific
221 d
222 RESTATEMENT (THIRD) OF TORTS: PROD. LIAB. § 6(d) (1998). See supra
notes 204-09 and accompanying text.
223 358 F. Supp. 2d 574 (E.D. Tex. 2005).
224 Thimerosal is a derivative of ethylmercury. Ethylmercury is a different
chemical than methylmercury, a known neurotoxin. Thimerosal is used as a
preservative; it is no longer added to most vaccines. Thimerosal in Vaccines,
FOOD & DRUG. ADMIN., http://www.fda.gov/biologicsbloodvaccines/
safetyavailability/vaccinesafety/ucm096228.htm (last visited Apr. 15, 2010).
225 Easter v. Aventis Pasteur, Inc., 358 F. Supp. 2d 574, 575-76 (E.D. Tex.
2005).
226 id
227 Id. at 575.
228 Id.
229 id.
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causation would have been present if the plaintiff had proved that
thimerosal caused the injuries to this specific plaintiff.230
In order to determine that the defendant's thimerosal-
containing product specifically caused Jordan's neurological
conditions, the plaintiffs' expert would have to eliminate other
potential causes for Jordan's injuries. 231 Even if thimerosal caused
autism in some recipients, other factors caused autism in patients
who were not thimerosal recipients.23 2 Since Jordan admittedly did
not have a genetic susceptibility to thimerosal, the court reasoned
that Jordan's neurological conditions were really aspects of his
autism. 233  Without Jordan having a genetic susceptibility to
thimerosal, the Easters could not prove specific causation, that
thimerosal caused Jordan's neurological conditions. 234 The court
excluded the plaintiffs' expert's testimony of a thimerosal-
neurological injury correlation because a thimerosal correlation
would not be relevant to this specific patient who is not genetically
susceptible to thimerosal.23 5 Thus, the proposed testimony would
not provide evidentiary proof of specific causation.236 Presumably,
if the plaintiffs had offered evidence demonstrating that Jordan had
the polymorphism that confers this genetic susceptibility, the judge
would have allowed the plaintiffs' expert to testify at the hearing.
In order to prevail in the lawsuit, the Easters would then have had
to prove the causal relationship between the manufacturer's
thimerosal-containing vaccine and autism in individuals with that
particular genetic susceptibility.
c. Failure to Warn
Manufacturers will often counter plaintiffs' failure to warn
causes of action with the learned intermediary or other causation
defenses.237 A failure to warn cause of action may prove successful
in jurisdictions that eliminate the learned intermediary defense
230 Id. at 576.
231 id
2321 d. at 577.
233 Id. at 579.
234 id
235 id.
236 id
237 See supra Part III.B. .a and Part III.B. 1.b.
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when a manufacturer engages in deceptive DTC advertising.23 8
The learned intermediary is also not a defense to the
manufacturer's failure to warn in vaccine lawsuits. 239 Thus, a
manufacturer's failure to warn patients of potential genetic
susceptibilities to a vaccine may be relevant to plaintiffs harmed by
undiagnosed warfarin genetic susceptibilities.
In Cassidy v. SmithKline Beecham, LYMErix vaccine patients
filed a lawsuit against SmithKline Beecham alleging that the
manufacturer's LYMErix vaccine caused the patients' treatment-
resistant arthritis due to the patients' HLA-DR4 genetic
susceptibility.240 The patients argued that the manufacturer had a
legal duty to warn the LYMErix vaccine's patient recipients of the
vaccine's arthritis potential in patients who have the HLA-DR4
genetic polymorphism. 241 The defendant argued that people who
have that HLA-DR4 genetic polymorphism have an independent
genetic susceptibility risk for treatment-resistant arthritis. The
vaccine does not increase that risk.2 42 The parties settled the case
prior to trial.243
The manufacturer's stance was probably correct. Although the
plaintiffs may have been able to prove that they had both the HLA-
DR4 genetic polymorphism and treatment-resistant arthritis,
proving general causation would have been problematic. The
238 See supra notes 216-18 and accompanying text.
239 The National Vaccine Injury Compensation Program establishes a no-fault
compensation process through the vaccine courts. A vaccine manufacturer is
not liable for injury from a faulty vaccine unless the plaintiff first tries the case
through the vaccine court, rejects the vaccine court's judgement, and then files a
civil lawsuit in a state or federal court. 42 U.S.C. § 300aa-11 (2006). In
situations outside of the vaccine court, the manufacturer can be liable for
damages. According to the Restatement (Third) of Torts, the learned
intermediary defense is not available to a manufacturer in a vaccine case or in
other cases in which the health care provider has less of an intermediary role
between the manufacturer and the patient. RESTATEMENT (THIRD) OF TORTS:
PROD. LIAB. § 6(d)(2), cmt. e (1998). Thus, the manufacturer has a duty to
directly warn the patient who receives the vaccine. Id.
240 Cassidy v. SmithKline Beecham Corp., No. 99-10423, 2003 WL 22216528
(Pa. Com. Pl. Jul. 1, 2003). SmithKline Beecham is now GlaxoSmithKline.
241 Id.
242 Id.
243 id.
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Centers for Disease Control and Prevention found no adverse event
evidence to substantiate linking those factors to the LYMErix
244vaccine.
A plaintiff claiming warfarin dosing injuries might successfully
sue a warfarin manufacturer for failure to warn patients of potential
genetic susceptibility to high or low warfarin dosages. Unlike the
situation in Cassidy, there should be no general causation hurdles.
There is ample evidence of warfarin sensitivity with specific
CYP2C9 and VKORCl polymorphism combinations and FDA
label recommendations for pharmacogenetic testing. Borrowing
the rationale from the Easter case, the manufacturer might
effectively argue that there is an absence of specific causation if
the plaintiff does not prove that the plaintiff has a particular
genetic susceptibility. In order to support an alternative causation
defense, the manufacturer could also petition for a court order that
would require the plaintiff to undergo genetic testing for other
genetic traits that might explain the plaintiffs injuries.24 Similar
to the plaintiffs' issue in the Easter case, a warfarin manufacturer
raising an alternative causation defense is not likely to prevail
unless the testing shows that the plaintiff actually has those
alternative genetic traits.246
If a Plaintiff can show a genetic basis to prove specific
causation, general causation may be a moot issue:
By shifting the specific causation inquiry from statistical
rules of thumb or subjective medical assessments to
molecular changes within the plaintiffs own cells, genetic
biomarkers such as gene expression signatures have the
potential to make specific causation significantly more
244 Sarah L. Lathrop et al., Adverse Event Reports Following Vaccination for
Lyme Disease: Dec. 1998-July 2000, 20 VACCINE 1603, 1607-08 (2002).
However, tepid demand coupled with the lawsuit's bad publicity forced
GlaxoSmithKline to withdraw LYMErix from the market. Andrew Clark, Tick
Puts Drugs Maker in the Rough, THE GUARDIAN (Mar. 7, 2002), available at
http://www.guardian.co.uk/business/2002/mar/07/medicineandhealth.1ifeandheal
th 1.
245 Gary E. Marchant, Genetic Data in Toxic Tort Litigation 14 J. L. & POL'Y
7, 12-13 (2006).
246 id
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objective and reliable. It may even obviate the need for
general causation, because if a party can directly show,
using gene expression markers, that a particular toxic agent
caused (or did not cause) his or her toxic response, that
party establishes causation without any need to make a
separate general causation finding.247
If specific causation issues are resolved, it is conceivable that a
patient with CYP2C9*3/*3, VKORC1-1639 AA alleles who is
injured by too high of an initial warfarin dose might argue that the
warfarin manufacturer failed to warn patients of this genetic
possibility. In the age of the Internet, a manufacturer may have
less success asserting the learned intermediary doctrine as its
defense. In response to this defense, might the plaintiff find
purchase arguing that a warfarin manufacturer has a duty to
recommend pharmacogenetic testing on its warfarin web site
because such sites amount to DTC advertising?
Similar DTC advertising issues arise with the warfarin label
which is also available online. Both the 2007 and 2010 Coumadin
labels contain the Information for Patients subheading under
Precautions.248 Neither labels' Information for Patients discusses
the patients' genetic susceptibility. The labels recommend that
patients should receive a manufacturer's Medication Guide, which
is at the end of the labels.249 Yet neither patient Medication Guide
warns patients of their potential genetic susceptibility, an omission
that may result in manufacturer liability.
2. Pharmacist and Health Care Institution Liability
A pharmacist has a legal duty to exercise "reasonable care"
when selling a prescription drug. 250 If a patient's injury is caused
by the pharmacist's failure to exercise that reasonable care, then
the pharmacist may be subject to liability.
247 Id. at 27.
248 BRISTOL-MYERS SQUIBB Co. (2007), supra note 7, at 19-20; BRISTOL-
MYERS SQUIBB Co. (2010), supra note 6, at 20-21.
249 BRISTOL-MYERS SQUIBB Co. (2007), supra note 7, at 31-34; BRISTOL-
MYERS SQUIBB Co. (2010), supra note 6, at 34-39.
250 RESTATEMENT (THIRD) OF TORTS: PROD. LIAB. § 6(e)(2) (1998).
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Reasonable care encompasses duties beyond the physical
processing of the prescription. 251' This is a negligence, not a strict
liability, standard. 252 A pharmacist's professional responsibility is
based on the knowledge that the pharmacist is expected to have.253
This knowledge determines whether the harm to the patient was
foreseeable. 254 However, this presumed knowledge base expands
as pharmacists increasingly become more involved in patient care,
as when pharmacists manage anticoagulation clinics.
In Jeffries v. United States, the plaintiff, Mr. Eason, received
anticoagulation therapy treatment at a veteran's hospital
anticoagulation clinic managed by Dr. Paysinger, a clinical
pharmacist. 255 Dr. Paysinger lowered the patient's warfarin prior to
the patient's planned dental surgery. The plaintiff alleged that Mr.
Eason's subsequent stroke resulted from Dr. Paysinger continuing
Mr. Eason on warfarin, despite an INR well below the patient's
target treatment range, instead of administering a faster-acting
heparin product.256 Dr. Paysinger testified that she did not
administer a heparin product because she was concerned about the
patient's bleeding risks.257
The court agreed that Dr. Paysinger's conduct fell below the
standard of medical care258 based on the plaintiffs two physician
experts and partially on the defendant's physician expert
testimonies.25 9 Although the defendant's physician agreed with the
plaintiffs experts as to a physician 's standard of care, he testified
251 David B. Brushwood & Bernadette S. Belgado, Judicial Policy and
Expanded Duties for Pharmacists, 59 AM. J. HEALTH-SYS. PHARMACISTS 455,
457 (2002).
252 id
253 Id.
254 id.
255 Jeffries v. United States, No. C08-1514RSL, 2009 U.S. Dist. LEXIS
102021 at *2 (W.D. Wash. Oct. 28, 2009).
256 Id. at *7-8.
2 571d. at *10.
258 Id. at *7-8.
259 The court discussed the expert physician testimony in an earlier hearing on
a motion for summary judgment. Jeffries v. United States, No. C08-1514RSL,
2009 U.S. Dist. LEXIS 89284 at *7-9 (W.D. Wash. Sept. 28, 2009).
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260that he was not familiar with a pharmacist's standard of care.
The court quoted the appropriate, objective standard of care as one
that is "ordinarily possessed and exercised by a minimally
competent and reasonably diligent, skillful, careful, and prudent
physician in that field of practice. ... "261
The concern with this decision for future pharmacist liability is
that the court held Dr. Paysinger to a physician's standard of care
despite the fact that Dr. Paysinger is a pharmacist, not a
physician.262 However, the broader implication may be that health
care institutions are particularly vulnerable due to the depth of their
pockets. It is important to note that the defendant in this case was
not Dr. Paysinger; it was the veteran's hospital.263 Perhaps one
lesson for a health care institution is that its responsibility for a
physician medical care standard in its anticoagulation clinic cannot
be delegated to create a lower standard of care threshold. With the
2010 warfarin pharmacogenetic testing label recommendations, a
health care institution may be held liable for their pharmacist or
other health care provider employee who does not order or
correctly interpret warfarin pharmacogenetic testing.
3. Physician Liability
Physicians, as well as other health care professionals, are liable
for standards of care based on negligence, not the strict liability
standard to which pharmaceutical manufacturers are held. 2" That
260 Id. at *8-9.
261 Id. at *13 (emphasis added).
262 David Brushwood is an attorney and Professor of Pharmacy at the
University of Florida. Brushwood & Belgado, supra note 251, at 1. After the
September Jeffries decision, he warned, "[t]his case is important, because it
confirms that pharmacists who manage drug therapy will be held to the standard
of physicians who do the same ... ." Memorandum from David Brushwood to
Practicing Pharmacists (Sept. 28, 2009), available at
http://pharmreg.dce.ufl.edu/JvUS.pdf.
263 Jeffries v. United States, No. C08-1514RSL, 2009 U.S. Dist. LEXIS
102021 at *8 (W.D. Wash. Oct. 28, 2009). The court emphasized that the
hospital's inability to adequately find and track its medical records was a
contributing factor to the patient's injuries in addition to the negligence of its
agent Dr. Paysinger. Id. at *9,*15-16.
264 Guillaume Sillon et al., Ethical and Legal Overview of
Pharmacogenomics: Perspectives and Issues, 27 MED. & L. 843, 855-56
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standard of care for physicians encompasses patient diagnosis and
making patient treatment decisions with the patient by getting
informed consent for treatment.26 5 This involves providing enough
material information so that the patient can weigh the risks and
benefits to be able to give informed consent.26 6 The physician must
accomplish all of this while adhering to the standards inherent in
their fiduciary relationship with their patients: to look after their
patients' best interests by staying current in their fields of
specialty.26 7
Pharmacogenetics adds another interesting wrinkle. Physicians
may have a fiduciary duty to make pharmacogenetic treatment
recommendations. 268  This would require the physician to know
when to order genetic tests, which tests to order, where to send the
patient to be tested, and how to interpret the results. In the case of
warfarin sensitivity, with conflicting clinical utility assessments,
their roles have become much more complex.
a. Genetics Quandary
It was not until December 27, 2001 that the American Society
of Human Genetics and the Association of Professors of Human
and Medical Genetics developed guidelines recommending genetic
classes in medical schools' core curriculum.269 Consequently,
(2009). This analysis is also applicable to nurse practitioners, and other health
care professionals who provide the same role as physicians with regard to a
patient's warfarin therapy management. Id.
265 Id. at 855.
266 d
267 id.
268 id
269 Association of Professors of Human and Medical Genetics/American
Society of Human Genetics, Medical School Core Curriculum in Genetics,
http://genetics.faseb.org/genetics/aphmg/med-sch-guide.htm [hereinafter
APHMG/ASHG]. APHMG has recently updated it to incorporate new issues in
genetics including the Genetic Information Non-Discrimination Act.
Association of Professors of Human and Medical Genetics, Medical School
Core Competencies in Genetics 2010, available at
http://www.aphmg.org/pdf/Med%20Competencies.pdf (last visited Apr. 16,
2010). See also Deanne M. Robinson & Chin-To Fong, Genetics in Medical
School Curriculum: A Look at the University of Rochester School of Medicine
and Dentistry, 9 J. ZHEJIANG U. Sci. B. 10, 10 (2008).
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physicians who graduated from medical school prior to 2002 may
not have had much in the way of genetics training.
In a more perfect world, a physician might rely on the services
of professionally-trained geneticists. Unfortunately, there are few
board certified genetic counselors and medical geneticists, the
professionals best equipped to explain genetic test results.270 For
example, in Arizona there are only twenty-seven genetic
counselors who are members of the National Society of Genetic
Counselors, 271' and limited certified geneticist272 curriculums exist
in Arizona. 273 There are approximately 509 physician-geneticists
scattered unevenly across the United States; 274 Arizona has
between one and five of them.275
The few genetic counselors who are available nation-wide are
seldom subject to any state licensing regulations.2 76 Yet, they and
physician-geneticists are far better equipped to recommend,
interpret, and explain pharmacogenetic tests than medical
providers untrained in genetics. 277 By default, physicians who are
270 How Do I Become a Certified Genetic Counselor (CGC@)?, AM. BD. OF
GENETIC COUNSELING, http://www.abgc.net/english/View.asp?x=1777 (last
modified Oct. 23, 2009) (showing requirements to become an ABGC certified
genetic counselor).
271 Find a Genetic Counselor - by US Zip Code, NAT'L SOC'Y OF GENETIC
COUNSELORS, http://www.nsgc.org/tabid/69/Default.aspx (last visited Nov. 24,
2010).
272 The American Board of Genetic Counseling certifies genetic counselors.
273 Gary E. Marchant, Executive Director & Faculty Fellow, Center for Law,
Science & Innovation at Arizona State University College of Law, Class lecture
in Genetics and the Law (Aug. 29, 2008).
274 Although, the American College of Medical Genetics ("ACMG") estimates
that there are approximately 1,100 medical doctor geneticists and 2,440 board-
certified genetic counselors in the United States, which ACMG also considers
inadequate. Shortage of Physician-Geneticists in the United States, THE
PERSONAL GENOME, http://thepersonalgenome.com/2007/12/shortage-of-
geneticists-in-the-united-states/ (last updated Jan. 2, 2007).
275 Id.
276 Only eleven states have passed some type of genetic counseling licensure
laws. Michigan: At the Forefront in Genetic Legislation Education: State
Licensure, MICHIGAN GENETICS CONNECTION, http://www.magcinc.org/
documents/MichiganGeneticLegislation.pdf (last visited Nov. 12, 2010).
277 Prior to 2002, physicians were not routinely trained in genetics. See
APHMG/ASHG, supra note 269 and accompanying text.
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not geneticists must increasingly risk liability to perform these
genetic functions.278 It is not surprising that many physicians resist
changing their practices to include pharmacogenetic testing when
they have so little access to both genetic training and genetics
experts to help them.2 79 Yet, physicians and other health care
professionals with little genetics training have the most risk of
liability for their failure to incorporate pharmacogenetics.2 80
b. Issues in Determining the Standard of Care
It is difficult for a physician to establish what the standard of
care is for treating warfarin patients. One of the problems is that
by its very nature, patient CYP2C9 and VKORC1 warfarin
sensitivity testing occurs at the same time as the initial warfarin
dosing.2 8' Therefore, it is difficult to determine whether the
clinical utility is from the warfarin or from the warfarin
pharmacogenic test.28 2 An adverse event related to the test may be
reported as a failure of the medication and vice versa:
For drugs with known or suspected genetic variability of
patient response, adverse-event reports may need to include
information about whether a TAB [treatment-adaptive
biomarker] test was performed at all and, if so, which
specific test was used; what the test result was; and whether
the clinician's decision to prescribe the drug was in line
with the current understanding of which drugs are
appropriate for patients with similar test results. This level
of detail is needed to support future improvements in drug
targeting ... 283
In part, this may explain the disparate warfarin study results.
The fact remains that often the only way physicians can identify
the warfarin patients at either extreme of sensitivity is from the
results of their patients' FDA label recommended CYP2C9/
278 Michael J. Malinowski, Coming into Being: Law, Ethics, and the Practice
ofPrenatal Genetic Screening, 45 HASTINGS L.J. 1435, 1493 (1994).
279 Gary E. Marchant, Personalized Medicine and the Law, 44 ARIZ. ATT'Y
12,16 (2007).
280 id.
281 See supra Part II.
282 Evans, supra note 162, at 761.
283 Id. at 771.
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VKORC1 testing. Patients' phenotypical characteristics have not
been as reliable for predicting safe initial dosing.284
A plaintiff could conceivably argue that the 2010 Coumadin
revised label dosing recommendations create a new standard of
care that requires warfarin pharmacogenetic testing concurrent
with initial warfarin dosing. An issue inherent in that argument is
whether the FDA's regulatory actions that produced these new
label recommendations preempt more lenient physician prescribing
practices under state tort law.
In most jurisdictions, a plaintiff who sues a physician for
medical malpractice must prove that the defendant did not meet the
standard of care (knowledge and skill) of physicians "in good
standing in similar communities." 285  Thus, a physician will likely
respond to the plaintiff's argument by asserting that the FDA's
dosing recommendations do not necessarily represent local
medical practice standards of care. In fact, in some situations
where the FDA label has not kept pace with scientific discoveries,
off-label use may constitute the safest standard of care in the
medical community. 286 However, other off-label uses may be
dangerous if physicians ignore screening tests which indicate that
the patient is at high risk for having an adverse reaction287 (as when
a physician prescribes an average warfarin dose despite the
patient's genotypical results indicating a very high warfarin
sensitivity and hemorrhage risk). In the latter scenario, with the
gathering of individualized patient pharmacogenetic information,
FDA "product regulation necessarily touches matters traditionally
284 See supra notes 48, 62-64, 103 and accompanying text.
285 RESTATEMENT (SECOND) OF TORTS § 299A (1965).
286 Off-Label Drug Use and FDA Review of Supplemental Drug Applications:
Hearing Before the Subcomm. on Human Resources and Intergovernmental
Relations of the H. Comm.on Governmental Reform and Oversight, 104th Cong.
11-12 (1996) (statement of Sarah Jaggar, Director of Heath Services Quality
and Public Health Issues). See supra notes 219-22 and accompanying text.
287 Barbara J. Evans, Seven Pillars of a New Evidentiary Paradigm: The
Food, Drug, and Cosmetic Act Enters the Genomic Era, 85 NOTRE DAME L.
REv. 419, 509 (2010).
153FALL 2010]
N.C.J.L. & TECH.
seen as medical-practice issues.... " ;288 hence, the need for a Wyeth
v. Levine... permitted FDA preemption in this area.
In Wyeth, the Vermont courts found that the plaintiff s arm was
amputated due to gangrene caused by a clinician's use of an
intravenous ("IV")-push method to inject a medication into the
plaintiff's arm instead of the safer IV-drip method. 290 The Vermont
Supreme Court affirmed that the drug's manufacturer, Wyeth, was
liable to the plaintiff due to Wyeth's failure to warn clinicians of
the heightened gangrene risks associated with the IV-push
injection method.29' Wyeth appealed the decision to the United
States Supreme Court arguing that the FDA's actions in approving
the drug's label without the IV-push injection gangrene warning
preempted the state's product liability claims.292
In denying Wyeth's federal preemption claim, the Court noted
that the FDA sets federal labeling standards as "minimal
standards" or "a floor upon which States could build" by adding
state labeling requirements.2 93 Wyeth does not preclude federal
preemption on a case by case basis depending "on the substance of
state and federal law." 294 The Court has given some deference to
an agency's preemption position in cases where "'the subject
matter is technica[l] and the relevant history and background are
complex and extensive."295
The Wyeth decision points out that the state standard, requiring
the IV-push method gangrene warning, disclosed more consumer
safety risks than the minimum standard in the FDA label which
omitted that warning.2 96 Whereas, a state standard, initiating
warfarin dosing without warfarin pharmacogenetic testing, would
disclose less consumer safety risks than the FDA's 2010 label
288 id.
289 Wyeth v. Levine, U.S._, 129 S. Ct. 1187, 173 L.Ed.2d 51 (2009).
290 Id. at 1191-92.
291 Id. at 1193.
292 id
293 Id. at 1202.
294 Id. at 1200-01.
295 Id. at 1201 (quoting Geier v. Am. Honda Motor Co., 529 U.S. 861, 883
(2000)).
296 Id. at 1196-97.
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recommending that testing. Applying Wyeth, it would certainly be
plausible for a court to rule that the warfarin label's
pharmacogenetic dosing recommendation sets a minimum federal
safety standard that warrants federal preemption when state law
fails to meet that minimum standard, especially given the
extensive, complex, technical debate regarding the clinical utility
of warfarin pharmacogenetic testing.
IV. CONCLUSION: BETWEEN A ROCK AND A HARD PLACE
A. The Status Quo
Will the FDA's 2010 changes to the warfarin label finally
provide the legal impetus for warfarin pharmacogenetic testing?
The legal impetus exists, but cost considerations may ultimately
defeat the promise of warfarin pharmacogenetic testing. One of
the problems that physicians and other health care providers may
encounter with their new found genetic duties is that a typical ten
minute office visit will be insufficient. Health clinicians who want
to take advantage of warfarin pharmacogenetic testing for their
patients must have the time to explain the feasibility of genetic
testing needed in order to get the patient's informed consent, and to
later explain the results of that testing.
Patient out-of-pocket cost for the extra office visits and the
pharmacogenetic testing result in a health care conundrum. The
logistics for acquiring timely third party coverage for warfarin
pharmacogenomic testing is daunting. Most patients who are
prescribed warfarin are older than average; many will be on
Medicare. The clinician would have to prescribe the Medicare
patient's first warfarin dose while simultaneously enrolling the
patient in a Medicare approved clinical trial that studies the clinical
utility of warfarin pharmacogenetic testing. Otherwise, Medicare
will not cover the pharmacogenetic costs, or presumably, the
associated counseling required. Most private insurers also do not
cover CYP2C9/VKORC1 warfarin sensitivity testing. If the
patients are unwilling or unable to pay for the testing, the clinicians
are effectively prevented from providing their patients with what
may be the appropriate standard of care: pharmacogenetic testing
concurrent with initial warfarin dosing.
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Consequently, the net result of the 2010 label changes may be a
giant paper shuffle. Attorneys will advise clinicians to document
their patient recommendations for warfarin sensitivity testing. The
health care provider will then produce a form and ask their patients
to sign off that they are making informed decisions to waive their
rights to have the testing. Finally, the form will need to contain a
statement that the patients will not hold the clinicians liable for the
patients' testing refusals.
B. Recommendations for Change
The warfarin pharmacogenetic testing clinical utility and
funding debacle is a harbinger of the battles that lie ahead for
personalized medicine. In particular, there will be an inevitable
increase in pharmacogenetic testing prompted by new genetic-
medication associations. There need to be more efficient, flexible
processes to both evaluate and take advantage of pharmacogenetic
advances.
The 2010 Patient Protection and Affordable Care Act clinical
effectiveness testing and uniform health care standards mandating
this insurance coverage should eventually help to alleviate some of
these roadblocks, but the Act requires some administrative actions
in order to achieve PPACA's benefits in two areas.
First, before implementing an independent analysis of the
clinical utility of pharmacogenetic testing versus an alternative, the
government must establish an independent, non-government, non-
profit corporation, the Patient-Centered Outcomes Research
Institute. Funding for the Institute is available in a trust fund
beginning in 2010, but PPACA does not specify who is authorized
to establish this nonprofit corporation. Congress needs to either
amend PPACA § 6301(a)29 7 to grant that authority or pass
clarifying regulations so that the Institute can be established. With
all of the built in waiting periods, it will still take some time after
the Institute's establishment before it can become functional.
Second, the Secretary of Health and Human Services ("HHS") has
297 Patient Protection and Affordable Care Act of 2010, Pub. L. 11-148, 124
Stat. 119 § 6301(a) (2010) (amending Social Security Act § 1181(d)(6)(C)); 42
U.S.C. § 1320e(d)(6)(C) (2006).
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yet to define the specifics of what constitutes basic "essential
health benefits" in year 2014.298 HHS rules need to explicitly
address whether PPACA uniform health care standards and
essential health benefits require pharmacogenetic private and
public insurance coverage.
In the meantime, Congress and the FDA have a role to play by
implementing new legislation and FDA regulations. Despite the
confusion over clinical utility for warfarin pharmacogenetic
testing, there have been no serious issues raised as to the clinical
validity of the testing to detect warfarin sensitivity.
Applying the rationale in Wyeth, the FDA should draft a
regulation for public comment that FDA label recommendations,
that apply to pharmacogenetic testing for dosing recommendation,
set a minimum federal safety standard. That minimum standard
should warrant federal preemption when the state law standard
falls below the FDA's. The rationale justifying federal preemption
in this limited area is reiterated in Wyeth, "the subject matter is
technica[l] and the relevant history and background are complex
and extensive."29 9Alternatively, the FDA could again revise the
Coumadin label to make FDA approved warfarin pharmacogenetic
testing mandatory. However, that would require frequent, costly
warfarin label revisions to address to address changing parameters
of what constitutes a warfarin pharmacogenetic test since
technological advances are likely to result in updated tests. .
Ideally, in order to avoid the litigation that would likely follow
the above two alternatives, Congress should amend the Food and
Drug Administration Amendments Act of 2007300 to give the FDA
more statutory authority to determine when it should require
pharmacogenetic testing for existing prescription medications to
mitigate risks of serious injury in susceptible patients.
298 Patient Protection and Affordable Care Act of 2010, Pub. L. 11-148, 124
Stat. 119 § 1302(b) (2010); 42 U.S.C. § 18022(b) (2006) (laying out the
groundwork for essential health benefits requirements).
29 Wyeth, at 1201 (quoting Geier v. Am. Honda Motor Co., 529 U.S. 861, 883
(2000).
300 Drugs and Devices: Risk Evaluation and Mitigation Strategies, 21 U.S.C.
§ 355-1 (2006).
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